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ABSTRACT 
 
The accountable care organization (ACO) is a delivery reform initiative that was devised 
to focus on care, health, and cost; quality of care within these organizations is 
determined by a set of defined performance measures.  The primary goal of this study 
was to investigate how a care coordination intervention, targeted to patients assigned to 
the organization’s ACO, affected patients’ likelihood of meeting performance measures.  
This is a retrospective longitudinal analysis using a pre post with non-equivalent control 
group research design.  The sample included Medicare patients, age 66 and older, 
receiving care in a traditional clinic setting (n=718).  The intervention took place in 
2013, and data from the prior year were used to assess the change in patients’ 
performance over time.  Methods used included grouped logistic regression, logistic 
regression, and difference in differences analyses.  The results of these analyses show a 
positive association between care coordination and meeting defined performance 
measures for 1) all measures, 2) process measures, and 3) outcome measures.  When 
comparing the impact of care coordination on process measures and outcome measures, 
process measures were more readily impacted by this care coordination intervention.  
Care coordination was positively associated with patients meeting defined performance 
measures.  The results of this study can inform like organizations of an intervention to 
improve population health that does go beyond a structural change.  This study also 
forced the examination of CMS’ defined performance measures; having one set of 
measures used for dual purposes may not be an effective performance management 
strategy.  The performance measures have been highly validated for the purpose of 
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improved population health, but are doubling as criteria by which both organization’s 
and providers’ performance are being assessed.  Future research should examine the 
extent to which the evaluative criteria of defined performance measures are meetable 
and fair from a performance management purposes. 
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NOMENCLATURE 
 
A1c Glycated hemoglobin 
 
ACE Angiotensin converting enzyme 
 
ACO Accountable Care Organization 
 
BP Blood pressure 
 
CAD Coronary artery disease 
 
CAHPS Consumer Assessment of Healthcare Providers and Systems 
 
CMS Center for Medicaid and Medicare Services 
 
dL Deciliter 
 
FQHC Federally Qualified Health Center 
 
HbA1c Glycated hemoglobin 
 
IOM Institute of Medicine 
 
IVD Ischemic vascular disease 
 
LDL Low-density lipoprotein 
 
LVSD Left ventricular systolic dysfunction 
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NQF National Quality Forum 
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PPACA The Patient Protection and Affordable Care Act 
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CHAPTER I  
 
INTRODUCTION 
 
 
The American health care system is broken, with poorly designed care processes 
(Fanjiang, Grossman, Compton, & Reid, 2005) and barriers to accessing to care, creating 
fractures in the continuity of patient care.  The United States (U.S.) spends more on 
health care than any other nation, while experiencing relatively low health status.  In 
2014, the U.S. outspent all other nations on health expenditures, which accounted for 
17.5 percent of the gross domestic product, approximately $9,500 per person (Center for 
Medicaid and Medicare Services, 2015).  Yet still, America ranked last overall of 11 
industrialized countries included in the Commonwealth Fund report, with specific 
failings related to administrative cost, provider communication, duplication of testing, 
access to care, infant mortality, preventable deaths, healthy life expectancy, and 
coordinating care (Mahon & Fox, 2014).  
A search of PubMed for the terms “health care” or healthcare and fragmented in 
title or abstract revealed over 1000 results, the earliest dating back to 1970 in which 
Senator Ralph Yarborough wrote: 
“A major element in the solution to any problem is a precise identification of the 
problem. We see clearly that our healthcare system must be brought together to 
function in a more efficient and effective manner. We must overcome the 
fragmentation which currently exists in the provision of services” (Yarborough, 
1970, p. 411).  
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Nearing half a century later, researchers and practitioners continue to seek out means of 
increasing patients’ quality and consistency of care; care coordination offers a bandage 
to this existing fractured structure of health care.  The United States’ population 
increasingly suffers from chronic conditions which require ongoing care while the cost 
of care continues to rise. It is expected that by 2020, 157 million Americans will have at 
least one chronic condition; the cost burden of chronic diseases accounted for 78 percent 
of total health spending in 2009 (Thomas Bodenheimer, Chen, & Bennett, 2009).  
Therefore, testing new ways in which we can improve care while slowing the rate of cost 
growth is appropriate and is a focus of current funding initiatives and widely covered in 
the health care literature.   
The accountable care organization (ACO) is a delivery reform initiative that was 
devised to focus on care, health, and cost, passed under Section 3022 of the Patient 
Protection and Affordable Care Act (PPACA) in 2010 (Medicare & Medicaid Services 
2011), in an effort to encourage health care organizations to be more responsible for the 
care they provide.  This dissertation investigates how care coordination affected patients’ 
likelihood of meeting performance measures defined by the Centers for Medicare and 
Medicaid Services (CMS).  The results of these analyses will inform like organizations 
of a possible intervention that does go beyond a structural change, implementing a new 
process of care in an ambulatory care setting, focused on improving population health.  
The following sections provide an overview of this study’s purpose in addition to an 
introduction to: accountable care organizations, care coordination, and patient 
compliance. 
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1.1 Purpose of Study 
 
This study is an analysis of the effects of a care coordination intervention in a 
federally qualified health center; an additional registered nurse was hired solely to 
provide care coordination to a defined patient group with a focus on achieving set 
performance measures.    
 
1.2 Specific Aims 
 
1. To determine if the care coordination intervention was successful in improving 
patient-level performance measures in this ambulatory care setting. 
2. To determine if the care coordination intervention was successful in increasing the 
completion of the recommended lab test to measure blood glucose levels among 
diabetic patients (patient compliance/adherence). 
3. To examine any difference that receipt of care coordination made on patients’ 
success in 1) meeting process quality measures and 2) outcome measures. 
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1.3 Literature Review 
 
1.3.1 Accountable Care Organizations 
 
ACOs are defined as groups of providers and suppliers whose purpose is, "to 
promote accountability for a patient population and coordinate item and services...and 
encourage investment in infrastructure and redesigned care processes for high quality 
and efficient service delivery” (United States Congress, 2010, p. 313).  With the 
introduction of ACOs, the role of care coordination extends beyond helping patients 
mitigate a complex, disjointed system through guided navigation of services, but now 
also directly relate s to payments received by health care organizations.  Patient 
assignment to accountable care organizations is determined by the payer and is based on 
receipt of primary care services for public ACOs.  “[Medicare] beneficiaries are assigned 
to participating ACOs if they receive more primary care services from ACO providers 
than from any other provider group”; primary care is defined by evaluation and 
management service codes and encompass office or outpatient services, nursing facility 
services, rest home services, home services, and wellness visits (McWilliams et al., 
2013, p. 1527).  Since the introduction of this delivery reform initiative, the number of 
ACOs across the country has grown dramatically, reaching nearly 600 in 2015 (see 
Table 1).  
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Table 1. Total Number of Accountable Care Organizations  
 
Type of Accountable Care 
Organization 
2013 2014 2015 
CMS (Pioneer, Medical Shared 
Savings program, or the PGP 
Transition program 
134 368 426 
Other Accountable Care 
Organizations 
124 154 159 
(Calandra, 2015; Ghandi, 2015) 
 
 
 
The accountable care organization is a care delivery reform initiative that has 
created an environmental input, resulting in an increased focus on CMS’ defined 
performance measures (Huerta et al., 2016).  Member organizations of ACOs must 
report the defined measures for purposes of cost sharing/saving.  Each measure defines 
the population to which the measure applies (denominator) and the terms to meet that 
measure (numerator).  These measures are reported to CMS to determine quality of care; 
similar measures are used by private ACOs.  Organizations were paid for reporting all 
measures in Year 1; 25 out of the 33 measures were pay for performance in Year 2; 32 
of the 33 measures were pay for reporting in Year 3 (CMS, 2012).  Changes to the 
measures have occurred since their inception and are briefly covered in Chapter II, 
though the initial measures are the focus given the date of intervention.  This dissertation 
examines an intervention to coordinate patient care with a focus on process 
documentation and added communication to improve care delivery and meet defined 
performance measures.  Figure 1 depicts where in an established logic model of health 
systems’ transformation this intervention occurred. 
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Figure 1. Health Systems’ Transformation for Improved Quality and Cost Savings 
 
 
Source: (Huerta et al., 2016) 
 
 
 
1.3.2 Care Coordination 
 
The existence of information asymmetry in addition to the complexity involved 
with securing appropriate care is key to explaining the need of care coordination to 
improve health outcomes. Patients with varying levels of health literacy, navigating a 
fragmented system of care, benefit from the support and direction of care coordination.  
Combining the National Quality Foundation and the Agency for Healthcare Research 
and Quality’s definitions of care coordination, the American Nurses Association 
definition of care coordination is as follows: 
“Care coordination is (a) a function that helps ensure that the patient’s needs and 
preferences are met over time with respect to health services and information 
sharing across people, functions, and sites; and (b) the deliberate organization of 
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patient care activities between two or more participants (including the patient) 
involved in a patient’s care to facilitate the appropriate delivery of health care 
services” (ANA, 2012, p. 1). 
There is a wealth of literature on care coordination, though interventions differ greatly as 
do the targeted conditions.  The UCSF Evidence-based Practice Center conducted a 
synthesis of systematic reviews on care coordination for AHRQ which included 75 
review articles; care coordination was found to have improved patient outcomes across 
varying settings and disease conditions, though there was mixed findings related to the 
costs of differing care coordination interventions (McDonald et al., 2007).   
The Medicare population may be a particularly appropriate population on which 
to focus care coordination to realize cost savings. Health issues and associated costs tend 
to increase as individuals age, often requiring care from multiple providers, which can 
create additional fragmentation and lead to duplication of services and unnecessary 
medical testing.  “Between 2000 and 2002, the typical Medicare beneficiary saw a 
median of two primary care physicians and five specialists each year, in addition to 
accessing diagnostic, pharmacy, and other services” (Bodenheimer, 2008, p. 1064).  A 
study evaluating a care coordination intervention of Medicare patients, consisting of 
disease management, case management, and long-term care management, found total 
costs for the participating sample to be 15.7% lower than the control group (Atherly & 
Thorpe, 2011).   
Conversely, Berwick & Hackbarth estimated the cost of failed care coordination 
to Medicaid and Medicare to be between $25 and $45 billion in 2011 (Berwick & 
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Hackbarth, 2012).  This begs the question of how to determine types of care 
coordination interventions that will prove successful in increasing quality while 
remaining cost neutral.  Pikes and colleagues examined 15 randomized trials of care 
coordination to determine if hospitalization and health care expenditures were impacted 
through such interventions for Medicare patients; two of the programs showed 
significant differences in hospitalizations and three found expenditures to be less for the 
treatment compared to the control group (2009).  Their conclusion was in order for care 
coordination programs to be financially viable, moderate to severe patients should be 
targeted and should include in-person contact (Peikes et al., 2009). A qualitative study 
interviewing 21 experts in care coordination and primary care transformation identified 
four common characteristics of successful care coordination interventions: 
1. “They assume accountability for coordinating their patients’ care”,  
2. “They reach out to key care partners to build relationships and agreements so that 
they understand each others’ expectations and preferences”,  
3. “They support their patients when they go elsewhere for care”,  and 
4. “They establish connectivity for transmitting standardized information and 
communicating with care partners”. 
(Wagner et al., 2014) 
 
1.3.3 Patient Compliance/Adherence 
 
For the purposes of this study, compliance and adherence are used 
interchangeably to describe patients who follow recommended medical advice.  This 
definition specifically relates to hypothesis two; the purpose in testing whether diabetic 
patients receiving care coordination were more likely to comply with completing the 
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recommended lab testing was to determine if the intervention positively affected 
patients’ activation.  The term patient activation refers to having “the knowledge, skills, 
and willingness to manage one’s own health and health care” (James, 2013, p.1).  
Clinicians can assist patients in acquiring the requisite knowledge and skills, and can 
attempt to influence patients’ willingness to adhere to recommended treatment.  
“Adherence [to complex regimens of medication, diet, exercise, and self-monitoring] 
depends on clear instructions, supportive teams, and shared decision making about care” 
(Schoen et al., 2011, p. 2441).  Knowledge of chronic conditions has been shown to be 
significant in explaining the variance in  patient adherence to life style changes and 
medication (Alm-Roijer et al., 2004); one means of conveying knowledge of risk factors 
and chronic conditions is achieved through care coordination.  
According to a study reviewing the 50 years of patient adherence research, the 
average non-adherence rate is 24.8% when looking at all empirical studies published 
between 1948 and 1998; the type of adherence (e.g., medication, health behaviors) was 
shown to be a significant factor as were the resources held by patients (e.g., education, 
income) (DiMatteo, 2004).  Changing patients’ habits can be aided through health 
education and coaching, but ultimately the choice lies with the individual. DiMatteo and 
colleagues cited reasons for nonadherence to include: misunderstanding, forgetting, or 
choosing to ignore the recommendations of their provider regarding 
prevention/treatment of disease (DiMatteo, 2004). Care coordination can help to reduce 
nonadherence due to misunderstandings and can attempt to inform patients’ 
understanding on the benefits of recommended treatments, potentially impacting 
10 
patients’ level of activation.  In addition, care coordination provides patients with 
reminders and follow-up communication that can impact nonadherence due to patients’ 
forgetfulness.  
1.4 Organization of Dissertation 
This dissertation is composed of five separate chapters. Chapter I is an 
introduction to accountable care organizations, care coordination, and patient 
compliance.  Chapter II discusses the background of Donabedian’s structure, process, 
outcome framework, and relates it to performance measures, defined by the Centers for 
Medicaid and Medicare (CMS).  Chapter III details the methodology used to conduct the 
analyses, and builds on the information presented in Chapter II.  Chapter IV provides an 
interpretation of the results of the analyses.  And lastly, I conclude with a discussion of 
possible implications in Chapter V. 
11 
CHAPTER II 
BACKGROUND 
2.1 Theoretical Framework 
This study will utilize Donabedian’s Quality of Care Framework, which was 
developed to assess the quality of medical care (Donabedian, 1966).  Figure 2 depicts 
Donabedian’s Quality of Care Framework and includes the three original domains: 
structure defines the system's capacity for care delivery, process defines the means of 
care delivery, and outcome defines the effect of care delivery; CMS added patient 
experience of care as a fourth domain which is measured through patient satisfaction 
surveys (Kessell et al., 2015).  Structure includes facilities, equipment, personnel, and 
operational and financial processes supporting medical care (McDonald et al., 2007).  
Singer and Shortell cite "failure to integrate beyond structural level” as one of the ten 
potential mistakes to be made when implementing an accountable care organization 
(Singer & Shortell, 2011, p. 759), indicating changes in processes for delivering care are 
suggested to realize a successful ACO.  
Quality in health care is guided by a mixture of process and outcome measures, 
making performance management in health care arguably more complex compared to 
other industries.  Process measures are derived from evidence-based clinical guidelines 
and are intended to improve health outcomes by dictating best practice of care; outcome 
measures "focus on improvement to a beneficiary’s health as a result of the care that is 
provided"; process measures "capture a method by which health care is provided” 
12 
(Kessell et al., 2015, p. 778).  The outcome of accountable care organizations is 
measured through meeting the defined performance measures, which are a mixture of 
process and outcome measures (see Table 2 for a description and evaluation of the CMS’ 
performance measures), while maintaining/decreasing costs.  
Figure 2. Donabedian’s Quality Framework 
Sources: (Donabedian, 1966; McDonald et al., 2007) 
2.2 Center for Medicaid and Medicare Services’ Defined Performance Measures 
The Centers for Medicare and Medicaid Services has defined 33 performance 
measures, 20 of which are used as the dependent variables in the analyses described in 
Chapter IV. Table 2 briefly describes these measures and includes the equivalent 
National Quality Forum measure number, the endorsement date, the type of measure 
(i.e., process or outcome), and the benefits of/rationale for each measure provided by 
either the National Quality Forum or CMS.  The following is a more inclusive summary 
of the 20 performance measures used in this study based on the guidelines provided by 
CMS (Centers for Medicare and Medicaid, 2013).  Related information from recent 
meta-analyses and other studies specific to these measures are reported to confirm/call 
into question the validity of defined measures.  
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Performance Measure 14: Calls for patients over 6 months to receive an 
influenza immunization if an encounter is scheduled between October and March unless 
previous receipt is reported or if the vaccine is unavailable.  Performance Measure 15: Calls 
for patients 65 and older to receive a pneumococcal vaccine if they have not received this 
vaccine once in their medical history.  Healthy People 2010 set a target of 90 percent 
immunization coverage for both the pneumococcal and influenza vaccines; in 1998, 
immunization rates fell short in persons aged 65 and older at 46 and 64 percent, respectively 
(U. S. Department of Health and Human Services, 2000). The recommendation set forth 
by the U.S. Department of Health and Human Services in Healthy People 2010 supports 
performance measures 14 and 15.  Lin and colleagues analyzed the cost effectiveness of 
standing order programs to increase the rate of pneumococcal and influenza vaccination in 
outpatient settings for elderly patients and found such programs to be an "economically 
favorable investment"(Lin et al., 2013). 
Performance Measure 16: Calls for adult patients to have their BMI calculated, and 
to have a documented follow-up plan if their BMI falls within either the low or high 
extremities.  Objective 19-2 of Health People 2010 calls for a reduction in proportion of 
adults who are obese; the threshold for obesity was defined as a BMI of 30 kg/m2 [Weight 
(lb) / (Height2 (in2) x 704.5)] (United et al., 2000).  The focus on individual’s weight stems 
from known associations of obesity with disease (e.g., diabetes, heart disease, etc.).    
Both performance measures 17 and 25 focus on tobacco use.  Performance Measure 
17: Calls for adult patients to be screened for tobacco use every two years; brief cessation 
counseling (three minutes or less) must be provided to tobacco users unless there exists a 
medical or other allowable exclusion.  A meta-analysis of the effects of smoking in older 
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adults confirmed smoking to be an independent risk factor for cardiovascular events and 
mortality and found that cessation is beneficial in reducing these risks for this population 
(Mons et al., 2015).  Despite known benefits, providers may be less likely to provide tobacco 
cessation to older adults; potential reasons for this include: time constraints, it is not 
considered part of their role as care provider, it is unfair to ask older people to quit smoking, 
it could cause damage to the patient doctor relationship, and it is inappropriate given 
patients’ health status (Huddlestone et al., 2015).  Performance Measure 25: Calls for 
diabetic patients between 18 and 75 years old to be non-tobacco users.  The American 
Diabetes Association recommends that smoking cessation be included as routine care to 
mitigate risk of cardiovascular disease. (ADA, 2015).  Tobacco users become addicted to 
nicotine, making patient compliance to the recommendation of non-tobacco a questionable 
measure of care quality.  Most smokers are aware of the harmful nature of tobacco but 
continue use despite the negative health consequences; many tobacco users have a desire to 
quit using tobacco products, but there is a high degree of relapse (National Institute on Drug 
Abuse, 2012).    
  Performance Measure 18: Calls for all people aged 12 or older to receive a 
depression screening; a documented follow-up plan is required for individuals who screen 
positive for depression unless there exists a medical or other allowable exclusion.  Healthy 
people 2010 calls for an increase in the depression treatment; screening for depression 
allows for the identification of mental illness (U. S. Department of Health and Human 
Services, 2000).  The U.S. Preventive Services Task Force recommends depression 
screening for the entire adult population; this is contrary to the Canadian Task Force on 
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Preventive Health Care which does not recommend depression screening for adults of 
average risk (Whooley, 2016).   
Performance Measure 19: Calls for all patients between 50 and 75 years of age to be 
screened for colorectal cancer unless there exists a medical or other allowable exclusion.  
This measure can be satisfied by an annual fecal occult blood tests (FOBT) or having had 
either a flexible sigmoidoscopy within the last four years or a colonoscopy within the last 
nine years. The latter two means of satisfying this measure have little to do with the quality 
of care currently experienced. Adherence to annual screenings is low  with only 10.4 
percent of the eligible population reporting the use of FOBT in 2012 (Berger et al., 
2016). 
Performance Measure 20: Calls for women between 40 and 69 years old to receive a 
mammogram every 2 years.  A recent study found that mammography screening reduces 
related mortality, though statistical significance varies based on age; the U.S. Preventive 
Services Task Force recommends women between 50 and 74 be screened (Nelson et al., 
2016).  The benefits of mammography screenings for women in their forties is debated 
(Hellquist et al., 2015). 
Performance measures 21 and 24 both focus on blood pressure but within different 
populations. Performance Measure 21: Calls for patients with scheduled visits to be 
screened for high blood pressure; a documented follow-up plan is required but varies based 
on the result of the initial screening (guidelines provided in CMS, 2013).  Screening for high 
blood pressure is a preventive measure as there are often no symptoms associated with high 
blood pressure. Performance Measure 24: Calls for diabetic patients between 18 and 75 year 
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old to have a blood pressure of less than 140/90 mmHg.  Keeping blood pressure in control 
usually involves a change in lifestyle (e.g., diet and exercise).  
Performance measures 22 and 27 have a similar focus of controlling the blood 
glucose level of the diabetic population.  Performance Measure 22: Calls for diabetic 
patients to have a Alc level of less than 8.0 percent.  Performance Measure 27: This measure 
is a measure of poor A1c control in diabetics.  Since the organization's goal was to help 
patients move from poor control into controlled, this measure was inverted to be: Calls for 
diabetic patients to have an Alc level of less than 9.0 percent.  Prevention of diabetes related 
complications requires both medical and patient self-management; “For every 1 percent 
reduction in results of HbA1c blood tests, the risk of developing eye, kidney, and nerve 
disease is reduced by 40 percent while the risk of heart attack is reduced by 14 percent” (U. 
S. Department of Health and Human Services Health Resources and Services 
Administration, 2012, p. 1).  
Keeping patients’ low-density lipoprotein cholesterol (LDL-C) in control is the 
focus of the following three performance measures.  Performance Measure 23: Calls for 
diabetic patients to have an LDL-C of less than 100mg/dL Performance Measure 29: Calls 
for adult patients with IVD to have received a lipid profile in the last year and to have an in 
control LDL-C (i.e., less than 100/mg/dL).  Performance Measure 32: Calls for adult 
patients with coronary artery disease to have either a LDL-C of less than 100 mg/dL or to 
have a documented plan to lower their LDL-C which includes a statin prescription.  The 
LDL-C is used to predict an individual's risk of heart disease, and treatment decisions are 
largely based on the LDL-C value (American Association of Clinical Chemistry, 2013).  
Keeping the LDL-C level in control requires practicing healthy behaviors (e.g., diet, weight, 
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physical activity, non-use of tobacco, and limited alcohol use), managing chronic medical 
conditions, and adhering to prescribed medication.  Patients with higher levels of activation 
are more likely to prove successful at keeping LDL-C levels in control (Centers for Disease 
COntrol and Prevention, 2015); providers can only influence patient activation levels.   
Performance measures 26 and 30 both focus on the documented use of aspirin for 
patients with ischemic vascular disease.  Performance Measure 26: Calls for diabetic 
patients who have IVD and are between 18 and 75 years old to have documented use of 
daily aspirin or antiplatelet medication.  Performance Measure 30: Calls for adult patients 
with IVD to have documented use of aspiring or other antithrombotic.  Patients who are at 
high risk for cardiovascular events benefit from continuous use of low-dose aspirin; patient-
initiated discontinuation of aspirin use occurred in up to 30 percent of patients in the 32 
studies reviewed, and predictors of non-compliance included education, sex, depression, 
diabetes, and tobacco use (Herlitz et al., 2010). 
Performance Measure 28: Calls for hypertensive patients between 18 and 85 years 
old to have adequately controlled blood pressure (i.e., less than 140/90 mmHg).  To control 
hypertension, patients must be motivated, and motivation can improve through positive 
interactions with providers, building trust; healthy lifestyle modifications shown to lower 
blood pressure include weight reduction, increased physical activity, and moderating use of 
alcohol (Chobanian et al., 2003). 
Measures 31 and 33 relate to recommended prescriptions for patients who have a left 
ventricular ejection fraction (LVEF) of less than forty percent.  Performance Measure 31: 
Calls for adult patients with heart failure who have a LVEF of less than 40 percent to be 
prescribed beta-blocker therapy.  Performance Measure 33: Calls for adults with coronary 
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artery disease who are diabetic or have a LVEF of less than forty percent to be prescribed 
ACE inhibitor or ARB therapy.  “There is now conclusive evidence that β-blockers, 
when added to ACE inhibitors, substantially reduce mortality, decrease sudden death, 
and improve symptoms in patients with HF”(p. 156), despite substantial evidence,  many 
patients do not receive this treatment (Gheorghiade et al., 2003). 
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Table 2. Explanation of Intended Benefits of Performance Measures   
PM
1 PM 
Description
Rationale 
Measure 
Type
Date of 
Endorsement
2 
ACO #14 
NQF#0041 
Influenza 
Immunization 
“This measure is intended to promote annual influenza vaccination for all 
patients aged 6 months and older, thereby reducing the likelihood of patients 
contracting the disease and associated morbidity and mortality” (NQF, 2010, p. 
2).
Process August 2009 
ACO #15 
NQF#0043 
Pneumococcal 
Vaccination 
“The disease burden is large for older adults and the potential for prevention is 
high. Pneumococcal infections result in significant health care expenditures each 
year, and vaccination is safe and effective. Modest cash outlays for vaccination 
have been shown to result in substantial cost savings and significantly lower 
morbidity” (NQF, 2011, p. 3).
Process August 2009 
ACO #16 
NQF#0421 
Adult Weight 
Screening and 
Follow-up 
“Recent literature indicates nearly 50 percent of primary care physician visits did 
not include a record of the height and weight data necessary to calculate BMI” 
(NQF, 2012, p. 3). 
Process July 2008 
ACO #17 
NQF 
#0028 
Tobacco Use 
Assessment 
and Cessation 
Intervention 
“
This measure is intended to promote adult tobacco screening and tobacco 
cessation interventions for those who use tobacco products, thereby increasing 
the proportion of smokers who successfully quit which in turn results in a 
decreased risk for heart disease, stroke, and lung disease.“ (NQF, 2015, p. 2). 
Process August 2009 
ACO #18 
NQF 
#0418 
Depression 
Screening 
“
Depression causes suffering, decreases quality of life, and causes impairment in 
social and occupational functioning. It is associated with increased health care 
costs as well as with higher rates of many chronic medical conditions” (Medicare 
& Services, 2013, p. 33).  
Process July 2008 
ACO #19 
NQF 
#0034 
Colorectal 
Cancer 
Screening 
“Reductions in the deaths associated with colorectal cancer. Decreases in 
medical costs associated with colorectal cancer” (NQF, 2009h, p. 3). 
Process August 2009 
ACO #20 
NQF 
#0031 
Mammograph
y Screening 
“The intent of the measure is to improve secondary prevention of breast cancer 
in order to catch disease when it is early and more amenable to treatment. 
Breast cancer treatment costs in the U.S. total nearly $7 billion per year, of which 
$2 billion is spent on late stage treatment. Low-income women are less likely to 
have had a mammogram within the past two years, increasing their risk of late-
stage diagnosis and decreasing their chance of survival. Numerous trials and 
evaluations have clearly shown that mammography reduces the risk of dying 
from breast cancer” (NQF, 2009b, p. 3). 
Process August 2009 
*No longer
NQF endorsed 
as of October 
2012. 
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PM
1
PM Description Rationale 
Measure 
Type
Date of 
Endorsement
2 
ACO #21 
NA 
Adults who had 
blood pressure 
screened in past 
2 years 
“
Hypertension is a prevalent condition that contributes to important adverse 
health outcomes, including premature death, heart attack, renal insufficiency 
and stroke. The United States Preventive Services Task Force found good 
evidence that blood pressure measurement can identify adults at increased 
risk for cardiovascular disease from high blood pressure. The relationship 
between systolic blood pressure and diastolic blood pressure and 
cardiovascular risk is continuous and graded” (Medicare & Services, 2013, p. 
40). 
Process 
NA 
ACO #22 
NQF #0729 
Hemoglobin A1c 
Control (HbA1c) 
(<8 percent)  
“According to the American Diabetes Association, an estimated 23.6 million 
American children and adults have diabetes. Most people with diabetes have 
other risk factors, such as high blood pressure and cholesterol that increase 
the risk for heart disease and stroke. In fact, more than 65% of people with 
diabetes die from these complications” (Medicare & Services, 2013, p. 41). 
Outcome 
March 2011 
ACO #23 
NQF #0729 
Low Density 
Lipoprotein (LDL) 
(<100 mg/dL)  
Outcome 
ACO #24 
NQF #0729 
Blood Pressure 
(BP) < 140/90 
Outcome 
ACO #25 
NQF #0729 
Tobacco Non 
Use 
Outcome 
ACO #26 
NQF #0729 
Aspirin Use 
Process 
ACO #27 
NQF #0059 
Beneficiaries 
with diabetes 
whose HbA1c is 
<9 percent 
“While the Committee noted that there was no evidence supporting a 
particular threshold value for poor control, members acknowledged that 
HbA1c >9% is a reasonable cutoff given that risk has been demonstrated 
when values are greater than 9%”(NQF, 2014, p. 16) .
Outcome Renewed 
August 2009 
*Endorsed by
the NQF since 
2002. 
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PM
1
PM Description Rationale 
Measure 
Type
Date of 
Endorsement
2 
ACO #28 
NQF #0018 
Beneficiaries with 
hypertension whose BP 
< 140/90 
“The most frequent and serious complications of uncontrolled 
hypertension include coronary heart disease, congestive heart failure, 
stroke, ruptured aortic aneurysm, renal disease, and retinopathy. 
Better control of BP has been shown to significantly reduce the 
probability that these undesirable and costly outcomes will occur. 
Thus, the relationship between the measure (control of hypertension) 
and the long-term clinical outcomes listed is well established” (NQF, 
2009c, p. 7). 
Outcome August 2009 
ACO #29 
NQF #0075 
Beneficiaries with IVD 
with complete lipid 
profile and LDL control 
< 100mg/dl 
“Research has shown individuals with existing coronary artery disease 
can reduce their risk of subsequent morbidity and premature 
mortality by managing their cholesterol levels. Studies show that 
reducing high lipid levels will reduce cardiovascular morbidity and 
mortality”
 
(NQF, 2009e, p. 5). 
Outcome August 2009 
*No longer NQF
endorsed as of 
September 2014. 
ACO #30 
NQF #0068 
Beneficiaries with IVD 
who use Aspirin or 
other antithrombotic 
“Aspirin is the safer, more convenient and least expensive form of 
therapy in reducing cardiovascular events among men and women; 
reducing the number of strokes, MI, and other vascular events 
considerably” (NQF, 2009d, p. 4). 
Process August 2009 
ACO #31 
NQF #0083 
Beta-Blocker Therapy 
for LVSD CAD 
“This measure is aimed at improving the number of patients with HF 
who are prescribed beta-blocker therapy in the outpatient and 
inpatient setting, particularly the three beta-blockers proven to 
reduce mortality and recommended in the treatment of patients with 
heart failure and LVSD” (NQF, 2009a, p. 3). 
Process August 2009 
ACO #32 
NQF #0074 
Drug Therapy for 
Lowering LDL 
Cholesterol 
The expected benefits of this measure is an “improvement of lipid 
management and the number of patients on a statin as first line 
therapy” (NQF, 2009g, p. 3). 
Process August 2009 
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ACO #33  
NQF #0066 
ACE Inhibitor or ARB 
Therapy for Patients 
with CAD and Diabetes 
and/or LVSD 
The expected benefits of this measure is an “improvement in the 
number of patients with CAD who have diabetes or LVEF <40% who 
are prescribed ACE inhibitor or ARB therapy” (NQF, 2009f, p. 3). 
 
Process August 2009 
 
1 Centers for Medicare and Medicaid Services. "Accountable care organization 2013 program analysis: quality performance standards 
narrative measure specifications." (2013). 
 
2  
http://www.qualityforum.org/Measures_Reports_Tools.aspx  The date of endorsement for each measures was found in the 
respective Measures Section. 
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There have been some changes to the CMS quality performance measures since 
their inception in 2013.  This study focuses only on the 1) preventive health and 2) at-
risk population performance measures, which included 20 measures for the 2013 study 
year.  Changes to these measures include reducing the diabetes composite measure from 
five measures to two measures (i.e., only poor A1c control was retained and an eye exam 
was added to the performance measures).  The 2015 CMS Performance Measure 
Specifications (Center for Medicare and Medicaid Services, 2013) now include only 15 
measures, including the omission of: five diabetes measures, LDL control for 
beneficiaries with IVD (PM-29), and Drug Therapy for Lowering LDL Cholesterol (PM-
32) and the addition of: an eye exam for diabetics (DM-41) and an additional depression
measure (ACO-40).  Five other measures were added to “patient/caregiver experience” 
and “care coordination/patient safety” categories, including one additional CAHPS 
measure focused on the stewardship of patient resources and four care 
coordination/patient safety measures focused on unplanned admissions and 
readmissions. 
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CHAPTER III  
 
METHODOLOGY 
 
 
This chapter details the methods employed in conducting the analysis for this study, 
which included specifics of the study design and setting, intervention, study sample, 
hypotheses, plan for data analysis, and methodological limitations. 
 
3.1 Study Design and Setting 
This dissertation is a retrospective analysis of a natural experiment that took 
place in a federally qualified health center (FQHC) in Texas.  The invention occurred in 
2013 and can be concisely described as an addition of a registered nurse (RN) to provide 
care coordination for patients enrolled in their ACO, focusing on the metrics described 
in Chapter II (see section 3.1.1 for detailed intervention description). The performance 
measures set by CMS are collected by the organization and are used in this study as the 
dependent variables to measure change in the achievement of those measures, a proxy 
for quality of care.  Demographic data and disease states are included to control for 
individual level differences.  Further information on the study’s population is provided 
in section 3.1.2 and in Figure 3.  
 
3.1.1 Intervention Description 
The care coordination intervention consisted of adding one full time nurse care 
coordinator (NCC) to staff, specifically to develop a care coordination process and to 
individually manage the care of a defined Medicare population within a federally 
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qualified health center.  The responsibilities of this position were wide ranging and 
defined by that employee during an interview held on September 19, 2014.  The NCC’s 
sole focus was managing the care of the defined treatment group (members of the ACO).  
The services the NCC provided were decided autonomously in effort to help population 
members meet the defined performance measures.  At the onset of this project, the NCC 
spent training staff in each clinic location on the established process specific to changes 
in the EHR and how communication through the EHR (termed huddle notes) should be 
used to help achieve the performance measures.  Huddle notes can be described as 
summary information compiled by the NCC and shared with the provider specifying 
which tests (e.g., mammogram, colonoscopy, etc.) need to be ordered and other specific 
things to address (e.g., smoking cessation, BMI, etcetera).  This allowed the NCC to 
communicate patient specific information to patients’ providers directly through the 
EHR regarding patient specific information on the day of appointment. Additionally, 
clinicians were provided with checklists and patient education materials to simplify the 
steps of care management. This process promotes increased communication between the 
NCC and each provider. The NCC then audited the charts of treatment group patients the 
day after a scheduled appointment to stay apprised of their progress. 
Communication with the patient was key in successful management of patient 
care and was maintained largely through telephone calls made by the NCC.  This means 
of communication can provide 1) an opportunity to deliver patient education, 2) to 
collect self-report metrics, 3) to make an appointment for needed lab work, 4) to inquire 
about patient needs (e.g., transportation), 5) to make patients aware of area services (e.g., 
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transportation providers, food pantries, etc.), and 6) to offer support and answer 
questions patients have pertaining to their health condition/medications to ease potential 
patient anxiety.  Individual in person patient education appointments were also made to 
provide information on diet and exercise, tobacco cessation, the benefits of vaccination, 
the benefits of colon cancer screening, and the benefits of breast cancer screening.  
Follow-up phone calls were made a week following in person appointments. The NCC 
also made calls and sent letters to patients to remind them to make an appointment or 
schedule lab work. 
Another component of the NCC’s position included facilitating efficiency and 
reducing redundancy. This was done by “cleaning” patient charts: removing old orders 
from patients’ charts to ensure that charts were current.  During that process, past 
medical history was examined, searching for specialist appointments to be certain that all 
documentation from these appointments had been successfully added to patients’ charts.  
If notes from these appointments were missing, a request of information was made to 
secure that data.  This was done either directly through the EHR system or via fax. The 
NCC also makes an effort to pull recent data (e.g., vitals, lab results, immunizations, 
etc.) from hospital data as another avenue to avoid unnecessary duplication of services. 
  
3.1.2 Study Sample 
 
Secondary data from the Medicare population at a federally qualified health 
center in Texas comprise the sample used in this study.  Use of this data was approved 
by the Texas A&M University Institutional Review Board (IRB2014-0238D).  The 
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dataset included all Medicare patients who received care in 2012 and 2013; the final 
sample consisted of 718 unique individuals.  Age, encounter, and setting were 
exclusionary variables.  Patients that were under 66 years of age in Year 0 were 
excluded to focus the analysis on traditionally qualifying Medicare patients; those 65 
years of age would have only received care for a partial year (based on birth date), 
creating a difference in access to care for part of the calendar year.  Also, patients that 
did not have at least one encounter in both 2012 and 2013 were excluded; to understand 
any difference in patients’ outcomes, data from each year is required.  Finally, patients 
whose primary location was a nursing home facility were also excluded, leaving six 
different locations at which care was provided during the set time period.  Medical 
records in the nursing home settings did not utilize an electronic health record excluding 
these patients from the benefit of the above described intervention.  Figure 2 shows how 
the described exclusion criteria affected the total number of the population for Specific 
Aim 1; subpopulations were defined for Specific Aims 2 and 3 (and for tests of each 
individual measure; see Appendix A) based on qualifying for respective measures.  The 
main study population is defined in Figure 3. 
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Figure 3. Exclusion Criteria 
3.1.3 Data 
Data for this dissertation was provided by the organization for analysis, and 
included the Medicare population.  Patients have a calendar to year to meet the defined 
metrics; data from calendar years 2012 and 2013 were used for this study.  The unit of 
analysis is the individual. Figure 3 depicts the pre post with non-equivalent research 
design.  CMS looks at performance measures at the organizational level as the 
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percentage of patients that met the defined measures; this study did not aggregate patient 
level data to control for individual level, observable differences between the treatment 
and control groups.  
Figure 4. Research Design 
3.1.4 Key Variables 
The background section of this dissertation introduces the dependent variables 
used in this study, and the history of process and outcome measures.  There are no 
known studies that have used similar data to measure the success a care coordination 
intervention.  A recent study assessing the difference of Pioneer ACOs in both quality 
and cost used difference in differences analyses utilizing only the performance measures 
that were captured through claims data; this was a longitudinal analysis and not all of the 
33 measures were reported before 2012 (McWilliams et al., 2015). Similar to a study on 
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the implications of a policy change, Blue Cross and Blue Shield’s introduction of 
Alternative Quality Contracts, quality measures were binary with some measures being 
restricted to members with a specified disease; measures were pooled for aggregate 
quality analysis (Song et al., 2011). Prior studies support the use of payer’s quality 
metrics to be used to assess quality improvement; additionally, it seems appropriate to 
measure the success of this intervention against the criterion upon which it was devised.  
For the intervention year (2013), there were 33 measures defined by CMS, and 
this study utilizes 20 of those measures relevant to ambulatory care settings.  The aim of 
performance measures 1 to 13 is improved care; the aim of performance measures 14 to 
33 is improved health (Donald M Berwick, 2011).  Availability and applicability of 12 
of the unused measures explain their exclusions (i.e., CAHPS (measures 1-7) and patient 
safety (measures 8-12)); patient safety measures largely focus on inpatient facilities and 
are not applicable to the study setting.  Measure 13 is a binary measure of whether a 
screening for future fall risk was conducted within the calendar year.  This measure was 
excluded for two reasons: 1) to be conservative in estimating the effects of this 
intervention; documentation of this screening was not done in Year 0, and 2) to focus on 
two complete categories of measures (i.e., preventive care (measures 14-21) and at risk 
populations (measures 22-33)).  The future fall risk measure is the only measure in the 
patient safety category available in the data used for this study.  The 20 performance 
measures (i.e., 14 to 33) used in this dissertation as / or to create dependent variables 
encompass the measures in the preventive care and at risk population domains.  
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For each of the two years, binary data was provided describing which of the 20 measures 
patients qualified for, and of those, which measures were met.  A summary of the 
study’s dependent variables is provided in Table 3, specifying the variable’s definition, 
the unit of analysis, and the relevant specific aim.   
Table 4 provides a summary and description of the independent variables used 
for covariate adjustment of observable differences.  This includes age, sex, race, 
ethnicity, known disease states, and primary location of encounter.  The data only 
included the five disease states relevant to the defined performance measures: diabetes, 
ischemic vascular disease, coronary artery disease, hypertension, and heart failure.  
Dummy variables were created to indicate the presence of each disease; these data are a 
substitute for a traditional comorbidity index.  For primary encounter location, the 
location serving the largest number of patients was set as the reference group.  
 32 
 
Table 3. Dependent Variables 
Variables Categories Description Unit of 
Analysis 
Specific 
Aim 
Number of 
Successes  
 
 
1. All 20 measures 
 
2. Only process 
measures 
 
3. Only outcomes 
measures 
Count of the  number of 
performance measures 
for which each patient 
met 
Individual 1, 3 
Number of 
Attempts 
 
1. All 20 measures 
 
2. Only process 
measures 
 
3. Only outcomes 
measures 
Count of the  number of 
performance measures 
for which each patient 
qualified 
Individual 1, 3 
 Proportion  
 
1. All 20 measures 
 
2. Only process 
measures 
 
3. Only outcomes 
measures 
A number between zero 
and one representing the 
number of successes 
divided by the number of 
attempts. 
Individual Figures 8, 
9, 10 
Individual 
Performance 
Measures  
20 different 
measures (see 
Chapter II) 
Twenty dummy-coded 
variables representing 
individuals that 
succeeded in meeting 
each measure 
individually 
Individual  
 
Appendix 
Adherence 22 
 
 Dummy-coded variable 
representing individuals 
that succeeded in 
adhering to 
recommended test 
Individual 2 
Intervention  
(Care 
Coordination) 
 Dummy-coded variable 
representing individuals 
that received the 
intervention 
Individual 1,2,3 
Time  Dummy-coded variable 
representing the pre-
intervention or 
intervention year 
Individual 1,2,3 
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Table 4. Independent Variables 
Variables Description Unit of 
Analysis 
Specific 
Aim 
Age 75 and older 
Binary Measure of 
patients’ age; 66-
74=0 / 75 and older=1 
Individual 1, 3 
Diabetes 
Binary Measure of 
the presence of 
Diabetes 
Individual 1, 3 
 
Hypertension 
Binary Measure of 
the presence of 
Hypertension 
Individual 1, 3 
Ischemic Vascular 
Disease 
Binary Measure of 
the presence of IVD 
Individual 1, 3 
Heart Failure 
Binary Measure of 
the presence of HF 
Individual 1, 3 
Coronary Artery 
Disease 
 
Binary Measure of 
the presence of CAD 
Individual 1, 3 
Male Binary variable 
representing patients’ 
gender 
Individual 1, 3 
Race Categorical variable 
representing patients’ 
race 
Individual 1, 3 
Ethnicity Categorical variable 
representing patients’ 
ethnicity 
Individual 1, 3 
Primary Encounter 
Location 
Categorical variable 
representing primary 
location of patients’ 
encounters 
Individual 1, 3 
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3.1.5 Hypotheses 
 
Hypothesis 1: Care coordination is associated with a significant increase in patients 
meeting set performance measures. 
Hypothesis 2: Care coordination is associated with a significant increase in diabetic 
patients’ compliance to obtaining recommended lab work to measure blood glucose 
levels. 
Hypothesis 3: Care coordination is more strongly associated with patients’ success in 
meeting process measures compared to outcome measures. 
 
3.2 Empirical Models 
 
For each of the main hypotheses tested, either grouped logistic regression or 
logistic regression was conducted using Stata 12 (i.e., blogit for grouped data and xtlogit 
to account for repeated measures within panel data); the data used in this study are 
longitudinal (i.e., two data points, one in each calendar year); “the dependency, or 
correlation, among responses measured in the same individual is the defining feature of a 
repeated-measures design” (Larson & Sullivan, 2006, p. 238). “Blogit is the maximum 
likelihood estimator (the same as logit or logistic) but applied on data organized in a 
different way. Rather than having individual observations, [the] data are organized so 
that each observation records the number of observed successes and failures” (Stata, , 
p.6). In both cases, the dependent variable(s) is/are binary, coded as 1 indicating the 
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desired outcome, because it is assumed that the probability of an event occurring is 
P(Y=1).  
Using a proportion as a dependent variable requires specific methods to account 
for the data's bounded nature to produce interpretable results (Baum, 2008); grouped 
logit takes into account the number of successes and number of attempts obtained by 
maximizing a weighted logit-likelihood function (StataCorp, 2012). Blogit reports 
estimated coefficients transformed to odds ratios in addition to transforming both 
standard errors and confidence intervals (StataCorp, 2012).  Since care coordination is a 
shared intervention among treatment group members, and because the success of the 
intervention is being measured by patients’ achieving up to 20 performance measures, it 
is appropriate to look at the data as a blocked/grouped data (for hypotheses 1 and 3), 
giving equal weight to each measure in measuring the success of the intervention.  
Figures 5 – 7 depict hypothetical data of two different patients for each of the 
three different categories of grouped dependent variables used in the analyses for 
hypotheses one and three (all measures, process measures, and outcome measures). An 
analysis using the proportion as the dependent variable would treat the example data as 
equal because they have the same proportion despite that those proportions are based on 
a different number of measures.   The blocked approach accounts for differences in the 
number of measures included in each block.  
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Figure 5. Dependent Variables – All Measures 
 
 
Figure 6. Dependent Variables – Outcome Measures 
 
 
 
Figure 7. Dependent Variables – Process Measures 
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3.3 Limitations of Methodology 
 
Random assignment is often labeled the gold standard of research designs, but is 
often not possible in health services research given ethical questions and other 
difficulties that can arise. Randomization does ensure that differences between the 
treatment and control groups among study participants are a result of chance, controlling 
for extraneous differences, insuring internal validity (Radosevich, 2006). “The central 
concern of internal validity is whether the relationship between the treatment and the 
outcome is causal in the population under study” (West & Thoemmes, 2010, p. 19). In 
order to draw a causal inference, one must be able to rule out the threats to the internal 
validity. The untreated control group design with a pretest and posttest typically controls 
for all but four threats to internal validity; they include: selection-maturation, 
instrumentation, differential statistical regression, and local history (i.e., interaction of 
selection and history) (Cook et al., 1979).  Chapter IV reports the results of tests to 
determine group equivalency.  
The intervention group was not selected by clinic location or by provider, and 
may have modified providers practice in treating all patients.  In this case, there could 
have been a spillover effect in which the control group could have received additional 
care from their provider.  This limitation would underestimate the effectiveness of the 
intervention in comparison to usual care.  Additionally, ICD-9 codes were not included 
in the data which did not allow for severity adjustment.  Dual status is also unknown 
though nursing homes settings were excluded which may have partially excluded 
patients qualifying for Medicare due to disability.   
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CHAPTER IV  
RESULTS 
 
 
The data used for this dissertation includes the quality performance measures 
(see Chapter II) achieved in 2012 and 2013 by Medicare patients receiving care in a 
federally qualified health center in Texas.  The final sample size includes 718 unique 
individuals, using subpopulations of that sample to test hypotheses two and three.  
Appendix A houses descriptive statistics for the subpopulations that qualify for each 
individual performance measure in addition to individual difference in differences 
analyses testing the impact of care coordination on meeting each measure.     
 
4.1 Descriptive Statistics 
 
The main study population is approximately one third male, three quarters white, 
and nearly 40% Hispanic, with a mean age of 74 (see Table 5).  Approximately forty-
five percent of the population has 2 or more comorbidities (diabetes, heart failure, 
hypertension, or ischemic vascular disease; see table 4).  Patients included in this sample 
had an average of 3.68 visits in 2013, with a range of one to 14 visits. The mean number 
of providers seen by each patient in 2013 was 1.66 providers, with a range of one to six 
providers. The data used for this study contained treatment, time, primary location of 
treatment, patients’ comorbidities, and demographic information in addition to 
performance measures (i.e., attempts and successes) for each patient.  Missing values 
existed for some of the demographic information (i.e., marital status, race, and 
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ethnicity); in these instances missing demographic data was coded as a separate category 
for these variables (e.g., Married=39%, Single=50%, and Missing=11%).   
 
Table 5. Number of Known Comorbidities in 2013 
Number of 
Diseases Frequency Percent 
Cumulative 
Percent 
0 113 15.74 15.74 
1 276 38.44 54.18 
2 205 28.55 82.73 
3 76 10.58 93.31 
4 40 5.57 98.89 
5 8 1.11 100 
 
 
 
According to the Centers for Medicare and Medicaid Services, the prevalence of 
diabetes in adults age 65 or older living in Texas in 2013 was 29 percent; the prevalence 
of diabetes in the study population in the same year was 39 percent.   (Centers for 
Medicare and Medicaid Services, 2016). Sixty-one percent of the individuals 65 or older 
in Texas had Hypertension in 2013, compared to 82 percent in the study sample; 
seventeen percent of Texans, age 65 and older, had experienced heart failure in 2013, ten 
percent more than the prevalence found in the study population (Centers for Medicare 
and Medicaid Services, 2016).  It is not possible to accurately compare the study 
population’s prevalence of Ischemic Vascular Disease nor Coronary Artery Disease to 
the State’s prevalence because CMS uses “Ischemic Heart Disease” as their category, 
which is both a broader than Coronary Artery Disease and also more narrow than 
Ischemic Vascular Disease. 
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Table 6. Demographics Characteristics of the Study Population 
  Total 
Treatment 
Group 
Control 
Group 
N 718 276 442 
Male (%) 34% 39% 31% 
Age 75 plus (%) 41% 35% 45% 
Age Mean 74 73 74 
White (%) 73% 75% 71% 
Black (%) 8% 6% 10% 
Other Race (%) 5% 4% 5% 
Hispanic (%) 38% 41% 37% 
Non-Hispanic (%) 41% 33% 46% 
Married (%) 36% 40% 33% 
Single (%) 49% 49% 49% 
Diabetic (%) 39% 40% 38% 
Hypertensive (%) 82% 80% 83% 
IVD (%) 20% 19% 21% 
Heart Failure (%) 7% 7% 7% 
CAD (%) 17% 17% 17% 
 
 
 
4.2 Group Non-Equivalence 
 
Through an examination and comparison of the group’s demographics (see Table 6), 
and confirmed by chi-squared tests, significant differences exist between the treatment 
and control groups in age, sex, marital status, race and ethnicity; the groups were 
determined to be non-equivalent.  The variables race, ethnicity, and marital status did 
include missing data, so a missing category was created for each.  Chi-squared tests were 
run on the data both including the missing data category and after listwise deletion; 
marital status was not statistically significant once patients with missing data had been 
dropped.  The decision to run the models on all patients (including missing categories) 
was made to more accurately estimate the impact of the intervention on the target 
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population; listwise deletion omitted just over forty percent of the patient population 
(N=295).   
To better understand group differences, the pretest numerators (i.e., measures 
met), pretest denominators (i.e., measures qualified for), and the resulting proportion 
were reviewed.  The chi-squared test showed significant differences between the 
treatment and control groups for the numerator and for the proportion; the difference 
between groups in the denominator was null, suggesting that between group differences 
were not based on number of comorbidities, but were potentially related to severity.  
“When pretest differences do exist, the possibility increases that selection will combine 
with other threats additively and interactively” (Shadish et al., 2001, p. 138). Non-
equivalence presumes selection bias; the existence of pretests scores by group allows for 
exploration of threats to validity (Shadish et al., 2001).  Figure 8 shows that the means of 
the proportion of measures met by groups and time are reliably different as the initially 
lower scoring treatment group significantly surpassed the mean of the initially higher 
scoring control group.  “Statistical regression cannot explain why low performers 
reliably surpassed the high performers at posttest, though regression may have inflated 
treatment estimates” (Shadish et al., 2001, p. 143). 
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Figure 8. Proportion of Performance Measures Met by Group and Time 
 
 
 
 
 
4.2.1 Adjusting for Non-Equivalence between Groups 
 
Quasi-randomization can be determined by comparing the differences between 
the two groups using propensity score matching or through use of an instrumental 
variables. “The propensity score, defined as the conditional probability of being treated 
given the covariates, can be used to balance the covariates in the two groups, and 
therefore reduce this bias” (d’Agostino, 1998, p. 2265). However, because unmeasured 
variables can actually be cofounders, increasing bias (Brooks & Ohsfeldt, 2013), the use 
of instrumental variables is likely preferable.  A potential instrumental variable of 
“distance to primary treatment location” was identified and tested in an attempt to 
correct for between group differences; unfortunately “distance to primary treatment 
location” was not viable as it failed to meet a necessary assumption of appropriate 
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instrumental variables; the variable was not associated with treatment (Morshed et al., 
2009).  The decided method to correct for between group differences used in this study 
is covariate adjustment. 
 
4.3 Multiple Hypothesis Testing 
 
Multiple hypotheses testing increases the chance for Type 1 error; adjusting the 
significance level cut-off using the Bonferoni approach is an accepted, though 
conservative, method for accounting for multiple hypotheses testing.  In the course of 
this dissertation, 24 dependent variables were tested (i.e., each of the 20 performance 
measures, individually, patient compliance to A1c testing, and summary DVs of the 
successes and attempts for 1) all measures, 2) all process measures, and 3) all outcome 
measures.   Given the 24 models run, there is ~71 percent chance of coming up with 
significant findings that are not truly significant [1 – (1 – 0.05)24 ≈0.708].  Using the 
Bonferoni correction (α/n), the significance cut-off for this study is set at 0.002 (.05/24). 
   
4.4 Validity of Key Measures 
 
A substantial section of Chapter II was dedicated to not only discussing the 
connection of the performance measures to Donebidian’s Structure, Process, and 
Outcomes model, but also to providing documentation from the literature to compare to 
the support provided by the Centers of Medicaid and Medicare and the National Quality 
Forum for the performance measures used as the dependent variables for this study. 
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 4.5 Findings from Empirical Models 
 
4.5.1 Hypothesis 1 Results 
 
The analysis of hypothesis one (see Table 5) supports that care coordination is 
associated with an increase in patients meeting overall performance measures (OR= 
4.072, p=0.0000).  The log likelihood for this model was -7778.365 (Wald chi2=780.70, 
p=0.0000).  A visual depiction in the change experienced in meeting defined 
performance measures is depicted in Figure 7 and can be compared to Figure 8, showing 
consistent performance among the control group.  There is a positive protective 
association between the interaction of the care coordination intervention and time with 
patients meeting defined performance measures (OR= 4.0716, p=0.0000).  Care 
coordination was negatively associated with meeting defined performance measures 
(OR=0.6312, p=0.0000), a likely result of the difference in pretest scores between 
groups.  Results from the grouped logit model are presented in Table 6.  Other factors 
that were found to be significantly associated to patients meeting defined performance 
measures include the presence of diabetes, being of Hispanic ethnicity, and receiving 
care from Location C. 
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Table 7. Grouped Logistic Regression Model Results for All Performance Measures 
  
Odds 
Ratio 
Standard 
Error 
z P>z 95% Confidence Interval 
Care Coordination 0.631 0.033 -8.820 0.000 0.570 - 0.699 
Time 1.044 0.055 0.820 0.412 0.942 - 1.158 
Care 
Coordination*Time 
4.072 0.327 17.460 0.000 3.478 - 4.767 
Age 75 plus 1.044 0.040 1.120 0.263 0.968 - 1.125 
Diabetes 1.325 0.074 5.060 0.000 1.188 - 1.477 
Hypertension 1.164 0.066 2.650 0.008 1.040 - 1.301 
Ischemic Vascular 
Disease 
1.304 0.163 2.130 0.034 1.021 - 1.666 
Heart Failure 0.985 0.111 -0.130 0.896 0.789 - 1.230 
Coronary Artery 
Disease 
1.048 0.138 0.360 0.720 0.810 - 1.357 
Male 1.009 0.051 0.180 0.858 0.914 - 1.114 
Marital Status 
Single 1.029 0.049 0.590 0.552 0.938 - 1.128 
Unknown 0.959 0.060 -0.680 0.496 0.849 - 1.083 
Race 
Black 0.973 0.081 -0.330 0.742 0.826 - 1.146 
Other 0.877 0.074 -1.540 0.123 0.743 - 1.036 
Unknown 1.039 0.065 0.600 0.545 0.919 - 1.174 
Ethnicity 
Hispanic 1.199 0.059 3.670 0.000 1.088 - 1.321 
Unknown 1.088 0.056 1.660 0.098 0.985 - 1.203 
Primary Treatment Location 
Location B 0.858 0.089 -1.470 0.140 0.701 - 1.052 
Location C 1.665 0.195 4.360 0.000 1.324 - 2.093 
Location D 1.238 0.115 2.300 0.021 1.032 - 1.484 
Location E 1.151 0.105 1.540 0.124 0.962 - 1.376 
Location F 1.030 0.119 0.250 0.801 0.820 - 1.293 
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4.5.2 Hypothesis 2 Results 
 
In examining the demographic differences between groups, it is clear that this diabetic 
subpopulation differs between groups in race and marital status in addition to incidence 
of Hypertension and CAD (see Table 7). 
 
Table 8. Demographic Characteristics of the Diabetic Population 
  Total 
Treatment 
Group 
Control 
Group 
N 196 83 113 
Male (%) 35% 40% 31% 
Age 75 plus (%) 14% 11% 16% 
Age Mean 71 70 71 
White (%) 69% 81% 60% 
Black (%) 9% 5% 12% 
Other Race (%) 4% 1% 5% 
Hispanic (%) 57% 58% 57% 
Non-Hispanic (%) 29% 28% 30% 
Married (%) 41% 46% 38% 
Single (%) 45% 46% 45% 
Diabetic (%) 96% 96% 96% 
Hypertensive (%) 93% 89% 96% 
IVD (%) 25% 28% 23% 
Heart Failure (%) 7% 7% 6% 
CAD (%) 19% 24% 15% 
 
 
 
The mean of the binary measure of adherence in year 0 for the diabetic 
population (n=196) represents the proportion of the population to comply with the 
recommended blood glucose test.  To determine potential difference in mean pretest 
scores between groups, the means of the two groups were examined; 88% of the control 
group and 87% of the treatment complied with the recommended blood glucose test.  A 
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chi-squared test confirmed that there was no significant difference between the two 
groups in pretest scores.  Examining the posttest scores, it is clear that the treatment 
group experienced an increase in compliance in year 1, exceeding prettest scores, while 
the control group experienced a decrease from baseline.  In looking at the change in 
patient compliance and non-compliance between groups between year 0 and year 1 (see 
Figure 9), it is notable that the control group experienced an overall decrease in the 
intervention year (11 percent) while the treatment group experienced a slight increase 
(2.4 percent).  
 
Figure 9. Proportion of Compliance to Blood Glucose Testing by Group and Year 
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The analysis of hypothesis two (see Table 7) does not show an association 
between care coordination and diabetic patient compliance in completing the 
recommended lab test to measure blood glucose levels.  Only the main effects model 
would converge, given the smaller size of this subpopulation (N=196; see Table 8).  
Time was shown to be significant at 0.019, but, due to the multiple hypotheses tested in 
this study, the Bonferroni correction was calculated, redefining the significance level to 
be 0.002.  The strength of the relationship between time and outcome is likely a result of 
the decreased compliance demonstrated by the control group in year 1.  The log 
likelihood for this model was -163.671 (Wald chi2=8.19, p= 0.0422).  Given the model 
results, we must accept the null hypothesis that there is no difference between the 
treatment and control groups in complying with the recommended blood glucose lab test.   
 
Table 9. Logistic Regression Model Results of Patient Compliance 
  
Odds 
Ratio 
Standar
d Error 
z P>z 95% Confidence Interval 
Care Coordination 0.934 0.467 -0.140 0.891 0.350 - 2.490 
Time 0.390 0.157 -2.340 0.019 0.178 - 0.857 
Care 
Coordination*Time 
3.340 2.198 1.830 0.067 0.920 - 12.129 
 
 
 
4.5.3 Hypothesis 3 Results 
 
The analyses for hypothesis three (see Tables 11 and 12) supports that care coordination 
is associated with an increase in patients meeting both process and outcome performance 
measures.  A visual depiction in the change experienced in meeting defined performance 
measures is shown in Figure 10.  The sample qualifying for process measures does not 
 49 
 
differ from the sample reviewed for all measures under hypothesis 1 as many process 
measures are preventive in nature and intended for the entire population.  Qualifying for 
outcome measures is disease specific, thus the sample of patients subject to outcome 
measures is smaller (n=573).  In looking at the group characteristics of the population 
qualifying for outcome measures, gender, age, marital status, race, and ethnicity are 
significantly different between groups in this subpopulation (see table 9). 
 
Table 10. A Comparison of the Patients Demographics by Measure Type 
  Process Measures  Outcome Measures 
  Total 
Treatment 
Group 
Control 
Group 
 
Total 
Treatment 
Group 
Control 
Group 
N 718 276 442  573 218 355 
Male (%) 34% 39% 31%  34% 38% 31% 
Age 75 plus (%) 41% 35% 45%  38% 31% 43% 
Age Mean 74 73 74  74 73 74 
White (%) 73% 75% 71%  73% 78% 70% 
Black (%) 8% 6% 10%  8% 5% 10% 
Other Race (%) 5% 4% 5%  4% 3% 5% 
Hispanic (%) 38% 41% 37%  42% 44% 40% 
Non-Hispanic (%) 41% 33% 46%  38% 31% 42% 
Married (%) 36% 40% 33%  35% 41% 32% 
Single (%) 49% 49% 49%  49% 48% 50% 
Diabetic (%) 39% 40% 38%  46% 47% 45% 
Hypertensive (%) 82% 80% 83%  95% 93% 96% 
IVD (%) 20% 19% 21%  24% 23% 25% 
Heart Failure (%) 7% 7% 7%  7% 7% 7% 
CAD (%) 17% 17% 17%  21% 21% 21% 
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For both process measures and outcome measures, there is a positive protective 
association between the care coordination intervention and patients meeting the defined 
performance measures; the intervention (treatment*time) did have a stronger positive 
association with patients meeting process measures (OR=4.796, p=0.000) compared to 
outcome measures (OR= 2.849, p=0.000).  Care coordination had a negative association 
with meeting process measures (OR=0.535, p=0.000), a likely result of the difference in 
pretest results experienced by the treatment group for this category of measures. 
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Table 11. Process Measures - Grouped Logistic Regression 
  
Odds 
Ratio 
Standar
d Error 
z P>z 95% Confidence Interval 
Care Coordination 0.535 0.031 -10.710 0.000 0.477 - 0.600 
Time 1.049 0.052 0.950 0.341 0.951 - 1.157 
Care 
Coordination*Time 
4.796 0.434 17.320 0.000 4.016 - 5.727 
Age 75 plus 1.224 0.067 3.710 0.000 1.100 - 1.361 
Diabetes 1.115 0.055 2.210 0.027 1.012 - 1.227 
Hypertension 1.104 0.053 2.070 0.038 1.005 - 1.212 
Ischemic Vascular 
Disease 
1.400 0.143 3.300 0.001 1.147 - 1.710 
Heart Failure 1.096 0.084 1.190 0.234 0.943 - 1.273 
Coronary Artery 
Disease 
1.121 0.112 1.140 0.253 0.922 - 1.364 
Male 0.970 0.037 -0.800 0.426 0.900 - 1.046 
Marital Status 
Single 1.017 0.055 0.310 0.757 0.915 - 1.130 
Unknown 0.950 0.063 -0.770 0.439 0.835 - 1.081 
Race 
Black 0.926 0.074 -0.960 0.339 0.792 - 1.084 
Other 0.877 0.090 -1.280 0.201 0.716 - 1.073 
Unknown 0.995 0.064 -0.080 0.936 0.877 - 1.129 
Ethnicity 
Hispanic 1.190 0.064 3.200 0.001 1.070 - 1.323 
Unknown 1.109 0.068 1.690 0.091 0.984 - 1.250 
Primary Treatment Location 
Location B 0.729 0.055 -4.200 0.000 0.629 - 0.845 
Location C 1.689 0.199 4.440 0.000 1.340 - 2.129 
Location D 1.084 0.097 0.890 0.372 0.909 - 1.292 
Location E 0.962 0.076 -0.500 0.620 0.823 - 1.123 
Location F 1.005 0.115 0.040 0.967 0.803 - 1.257 
 
 
Other factors significantly positively associated to achieving defined process 
measures include: age (OR=1.224, p=0.000), IVD (OR=1.400, p=0.001), Hispanic 
(OR=1.190, p=0.001), and location C (OR=1.689, p=0.000).  Receipt of care from 
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location B was negatively associated with meeting process measures (OR=0.729).  Being 
75 years or older had a positive association, contrary the effect on outcome measures.   
 
Table 12. Outcome Measures – Grouped Logistic Regression 
  
Odds 
Ratio 
Standar
d Error 
z P>z 95% Confidence Interval 
Care Coordination 1.042 0.130 0.330 0.743 0.816 - 1.329 
Time 1.078 0.148 0.550 0.585 0.824 - 1.411 
Care 
Coordination*Time 
2.849 0.638 4.670 0.000 1.836 - 4.419 
Age 75 plus 0.656 0.075 -3.680 0.000 0.524 - 0.821 
Diabetes 1.042 0.145 0.300 0.766 0.793 - 1.369 
Hypertension 0.950 0.171 -0.290 0.773 0.668 - 1.350 
Ischemic Vascular 
Disease 
1.140 0.240 0.620 0.534 0.754 - 1.724 
Heart Failure 0.671 0.157 -1.700 0.089 0.424 - 1.063 
Coronary Artery 
Disease 
0.830 0.193 -0.800 0.422 0.526 - 1.308 
Male 1.080 0.123 0.670 0.501 0.864 - 1.350 
Marital Status 
Single 1.082 0.135 0.630 0.527 0.848 - 1.382 
Unknown 0.995 0.159 -0.030 0.973 0.727 - 1.360 
Race 
Black 1.357 0.268 1.550 0.121 0.922 - 1.998 
Other 1.006 0.284 0.020 0.983 0.578 - 1.751 
Unknown 1.239 0.188 1.410 0.158 0.920 - 1.669 
Ethnicity 
Hispanic 1.370 0.180 2.390 0.017 1.059 - 1.774 
Unknown 1.082 0.164 0.520 0.604 0.803 - 1.457 
Primary Treatment Location 
Location B 1.362 0.291 1.450 0.148 0.896 - 2.071 
Location C 1.649 0.439 1.880 0.061 0.978 - 2.779 
Location D 1.835 0.385 2.890 0.004 1.216 - 2.770 
Location E 2.061 0.401 3.720 0.000 1.408 - 3.016 
Location F 1.086 0.261 0.340 0.730 0.678 - 1.740 
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There are two other factors with a significant association to meeting outcome measures: 
age (OR= 0.656, p=0.000) and location E (OR=2.061, 0.000).  Being 75 years or older 
had a negative association with achieving outcome measures, while having location E 
increased the likelihood of patients meeting defined outcome measures.  
 
Figure 10. Proportion of Performance Measures Met by Type, Group, and Time 
 
 
 
 
4.5.4 Summary of Empirical Results 
 
A simple means of examining how care coordination affected patient success in meeting 
1) all measures, 2) process measures, and 3) outcome measure is to compare the mean 
proportion by group and time.  Looking at the difference between the years 0 and 1 for 
each group individually, it is clear that for all three measure categories the treatment 
group realized a much larger increase in proportion of success in meeting defined 
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measures.  Confirmatory analyses of the main effects, using difference in differences, for 
hypotheses 1 and 3 were conducted. Table 13 shows the proportion of measures met by 
group, pre and post measurement, by measure type.  These data confirm that the 
treatment group, despite the lower pretest score means, surpassed the control group in 
Year 1 in each of the three categories, and that there was no substantial change in mean 
scores for the control group.  A summary of results from all difference in differences 
analyses is listed in table 14; results for all measures, process measures, and outcome 
measures all show a statistically significant difference between groups by year 
(p=0.000). 
 
Table 13. Mean Proportion of Performance Measures by Group and Year 
  All measures Process Measures Outcome Measures 
Treatment 
* Time 
Treatment  
Group 
Control  
Group 
Treatment  
Group 
Control  
Group 
Treatment  
Group 
Control  
Group 
T0 (2012) 44% 54% 39% 53% 60% 60% 
T1 (2013) 79% 56% 76% 55% 88% 60% 
Difference 35% 2% 37% 2% 28% 0% 
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Table 14. Statistical Significance of Time*Treatment by Individual PM Measure 
Performance 
Measure(s) 
Measure Description Difference in 
Differences  
P>t 
Measure 
Type 
All Measures Performance Measures: 14-33 0.329 0.000** Both 
Process 
Measures 
Performance Measures: 14, 15, 16, 
17, 18, 19, 20, 21, 22, 26, 30, 31, 
32, and 33 0.353 0.000** 
Process 
Outcome 
Measures 
Performance Measures: 23, 24, 25, 
27, 28, and 29 0.268 0.000** 
Outcome 
PM 14 Influenza Immunization 0.145 0.021* Process 
PM 15 Pneumococcal Vaccination -0.088 0.098 Process 
PM 16 
Adult Weight Screening and Follow-
up 0.352 0.000** 
Process 
PM 17 
Tobacco Use Assessment and 
Cessation Intervention 0.973 0.000** 
Process 
PM 18 Depression Screening 0.737 0.000** Process 
PM 19 Colorectal Cancer Screening -0.092 0.101 Process 
PM 20 Mammography Screening -0.180 0.083 Process 
PM 21 
Adults who had blood pressure 
screened in past 2 years 0.428 0.000** 
Process 
PM 22 
Hemoglobin A1c Control (HbA1c) 
(<8 percent)  0.077 0.415 
Outcome 
PM 23 
Low Density Lipoprotein (LDL) 
(<100 mg/dL)  0.174 0.086 
Outcome 
PM 24 Blood Pressure (BP) < 140/90 0.254 0.009* Outcome 
PM 25 Tobacco Non Use 0.028 0.698 Outcome 
PM 26 Aspirin Use -0.020 0.932 Process 
PM 27 
Beneficiaries with diabetes whose 
HbA1c is <9 percent 0.064 0.453 
Outcome 
PM 28 
Beneficiaries with hypertension 
whose BP < 140/90 0.353 0.000** 
Outcome 
PM 29 
Beneficiaries with IVD with 
complete lipid profile and LDL 
control < 100mg/dl 0.049 0.698 
Outcome 
PM 30 
Beneficiaries with IVD who use 
Aspirin or other antithrombotic -0.018 0.838 
Process 
PM 31 Beta-Blocker Therapy for LVSD CAD 0.080 0.698 Process 
PM 32 
Drug Therapy for Lowering LDL 
Cholesterol 0.174 0.153 
Process 
PM 33 
ACE Inhibitor or ARB Therapy for 
Patients with CAD and Diabetes 
and/or LVSD -0.067 0.663 
Process 
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The difference in differences analyses for each performance measure allows for 
an examination of the individual effect of care coordination.  Table 14 details the 
difference in differences (between groups and years), indicating significance at  p<.05 
and p<.002;  the latter is used as the significance cutoff for this study, but the change in 
each of these performance measures is examined.  There was an increase in meeting 
performance measure 14 (i.e., influenza vaccine) of more than five percent among 
treatment group members, while the control group experienced a decrease of nearly ten 
percent.  Baseline pretests were equal between groups for performance measure 16 (i.e., 
BMI screening and documented follow-up), but the treatment group improved by over 
30 percent while the control group remained nearly consistent.  There was a striking 
distance between pretest scores for performance measure 17; this measure relates to 
tobacco use and cessation treatment and zero members of the treatment group met this 
measure in year 0 while 97 percent of the control group were either tobacco non-users or 
had been offered cessation counseling.  In year 1, the control group realized a slight 
increase, but 100 percent of the treatment group then met this measure.  Performance 
measure 18 focuses on clinical depression screenings.  Over fourteen percent of the 
control group met this measure in year 0, compared to seven percent of the treatment 
group; in year 1, the treatment group had increased their success by 70 percent while the 
control group realized a slight decrease in depression screenings.  Performance measure 
21 calls for blood pressure screening and documented follow-up for results of high blood 
pressure.  The treatment group's pretest mean was higher than that of the control group 
(41 percent and 28 percent, respectively), but the treatment group nearly doubled their 
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success in year 1 compared to a slight decrease of success by the control group.  The 
pretest results for performance measure 24 were equitable; this measure focused on 
blood pressure results of the diabetic subpopulation.  The treatment group increased their 
success by 25 percent while the control group realized a nearly 10 percent decrease.  
Performance measure 28 focuses on the blood pressure results of the diabetic, 
hypertensive population; differences between groups in pretest results were minimal.  
The treatment group in year 1 increased success in meeting this measure by over 20 
percent, while the control group remained largely unchanged.  When looking at the 
difference between the two groups by year, six individual measures realized a minimal 
decrease; it is notable that none of those decreases were statistically significant.  Seven 
measures showed positive significant changes; only two of those were outcome 
measures and both were related to blood pressure results. 
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CHAPTER V  
 
DISCUSSION AND CONCLUSIONS 
 
 
The main goal of this study was accomplished in assessing the effects that a care 
coordination intervention had on patients’ likelihood to meet defined performance 
measures.  Though both process and outcome measures of patients in the treatment 
group showed a statistically significant increase, the results suggest that efforts to 
coordinate care are more effective on performance measures in which providers have a 
higher degree of control (i.e., process measures).  Increased outcome measures may 
result from higher quality of care, but level of patient activation and patient adherence to 
medical advice likely mediates that relationship.   
In designing this study, the measures used to gauge quality became a subject of 
investigation.  It was necessary to consider if the defined CMS measures were 
appropriate metrics by which to judge the success of this intervention.  Given that these 
measures guided the care coordination intervention, it seemed reasonable to measure its 
success in this manner.  It does, however, also seem appropriate to discuss the potential 
fallacies/issues associated with this type of measurement.  This includes an examination 
of performance measures utilizing established management literature and concerns 
spelled out in recent literature. 
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5.1 Examining Performance Measures: A Performance Management Perspective 
 
Performance is difficult to accurately assess in the health care environment 
because there is a poor correlation between outcome and quality due to the low signal to 
noise ratio (i.e., factors other than quality of care affect outcomes) and case mix bias 
(i.e., some patients are sicker than others) (Lilford et al., 2007).  While it is difficult to 
define absolute best practices of performance management, given the context specific 
nature of performance management systems, the literature does offer broad suggestions 
to guide effective performance management.  Aguinas describes the ideal performance 
management system as including the following characteristics (2009): 
 
1. Strategic congruence  
2. Thoroughness  
3. Practicality  
4. Meaningfulness  
5. Specificity 
6. Effective/ineffective 
`performance 
7. Reliability 
8. Validity  
9. Acceptability/fairness 
10. Inclusiveness 
11. Openness  
12. Correctability  
13. Standardization 
14. Ethicality 
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What follows is a discussion of recommended performance management practices and 
how they align with the current healthcare environment based using the above identified 
characteristics as guidance.   
A basic premise of setting performance management evaluative criteria is to 
align individual goals with unit and organizational goals (i.e., strategic congruence; 
Aguinas, 2009).  Having payers set performance goals complicates aligning strategy and 
individual goals.  If we look at CMS or other payers as the organization and the ACO as 
the individual, we can largely assume alignment because participation in these networks 
is voluntary.  Given the expansive networks of healthcare organizations participating in 
ACOs, finding alignment between all these organizations and attempting to continue that 
alignment to include individual practitioners adds immense complexity, highlighting the 
importance of provider buy-in.  
The performance measures are thorough for the purpose of improving population 
health; they are not thorough as proxies for performance of the quality of care provided 
by an organization or by an individual physicians; all major job responsibilities should 
be evaluated.  A particular approach to performance management may be effective for a 
particular purpose, but what works in one context may not prove effective in another.  
DeNisi and Smith suggest that employees should be able to see how to achieve personal 
goals that are aligned with strategic goals (2014), and since quality care does not always 
lead to quality outcomes, being judged by these performance measurements may have 
unintended consequences (e.g., decreased job satisfaction and motivation, decreased 
perceived fairness/justice, and increased incidence of burnout).  Patient adherence can 
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affect performance measures that providers are striving to help patients achieve, making 
the achievement a joint effort.  The level of patient outcomes depends on a number of 
factors, only some of which are provider controlled.  Adherence to recommended 
medical advice varies because patients’ understanding of and willingness to manage 
their health varies by individual; the former has the potential to make vulnerable 
populations less desirable patients.  If the purpose in using these measures was more 
strictly focused on increasing population health, there would be little argument to the 
extent to which they are thorough. But since these measures are now also tied to 
payment, the organization is being judged on criteria not wholly within its control which 
tends to impact providers’ pay structures.  “When used for multiple purposes, 
[performance appraisal] systems should be designed for those purposes, e.g. separate 
objectives, measurement criteria, etc., for career development and for the work activity” 
(Banner & Graber, 1985, p. 31).  This is a crucial disconnect between the performance 
management literature and accepted performance management practices in the 
healthcare industry. 
Regarding practicality, time is required to collect and report the defined 
performance measures; in some cases, new technology, procedures, and/or staff may be 
needed to aid in accurate documentation and coordination of care.  And there has been 
some criticism of excessive reporting requirements.  A recent qualitative study of health 
care executives and physicians noted two disadvantages of ACOs directly tied to 
performance measures:  
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1) “Increased bureaucracy – in the form of committee meetings, quality measure 
reporting, patient-centered medical home documentation, etc.” and  
2) “Loss of autonomy due to expected adherence to clinical guidelines and 
performance on quality measures” (Berenson, Burton, & McGrath, 2016, p. 3). 
   
 Meaningfulness and validity refer to the evaluative criteria used in assessing 
performance; in this context, there is a degree of overlap between the two concepts as 
both relate to measure relevance.  Chapter II assessed the performance measures based 
on the current literature and the rationale for them; CMS does communicate and clarify 
providers’ responsibilities as the performance management literature suggests (Pulakos 
& O’Leary, 2011) and they are based on best practices of care, despite that some of the 
enumerated targets are beyond provider control.  The rationale for the performance 
measures provided by NQF and CMS are based on setting criteria that is beneficial to 
population health, which is only one purpose for which these measures are used.  
Providers and health systems need to understand in what ways and to what degrees a 
patient population is lacking in order to best address those concerns.  Those same 
standards are arguably not readily transferrable as evaluative criteria for organizations or 
providers, but the structure of accountable care organizations do/encourage just that.  
“Performance assessment must emphasise only those functions under the control of the 
employee” (Aguinis, 2009, p.1/15). Judging a widget maker’s work quality and 
productivity based solely on the functionality and number of widgets produced is logical.  
This simple means of assessment does not readily translate to the health care 
environment due to the variability in patient activation (i.e., knowledge, skills, and 
willingness).   
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The specificity of CMS’ performance measures are evident by the 73 page 
document used to describe the details of the 2013 measures.  A three year ethnographic 
study of four organizations in the United Kingdom’s National Health Service found that 
the "inflexible application of metrics-based target systems to clinical and administrative 
tasks...can result in dysfunctional outcomes for patient care and workforce morale” 
stemming from a dissatisfaction with the targets culture (McCann et al., 2015, p. 773).  
Having detailed guidance regarding performance expectations can allow employees to 
have a true understanding between effective and ineffective performance (Aguinas, 
2009).  This is not necessarily true when measures lack meaningfulness and validity, and 
herein lies the problem.   
What remains in question is to what degree these measures readily identify high 
performing organizations and providers.  “Outcomes synthesise all of the processes 
received by the patient and therefore reflect the activities of many clinicians and support 
services (Lilford et al., 2007, p. 649)”.  A focus on behaviors that are under the control 
of employees is appropriate (Aguinas, 2009; DeNisi & Smith, 2014) so as not to create 
unintended consequences.  Acceptability and fairness of defined measures system is 
achieved when participants in the performance management system find it to be fair and 
appropriate.   
The reliability of these performance measures should be consistent as data can 
readily be collected through use of an electronic health record at time of patient visit.  
Standardized systems should be used to evaluate consistently across people and time, 
(Aguinas, 2009), and in this way ACO performance measures comply.  The reporting 
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process is highly standardized, allowing for comparison of results across various ACO 
networks.  Correctability encompasses the idea of minimizing subjectivity, which these 
performance measures also do. 
The inclusiveness of these measures could be argued largely based on the dual 
role that these measure play in performance management (i.e., population health 
improvement and administrative purposes).  An inclusive evaluation process “must 
represent the concerns of all the people who will be affected by the outcome” (Aguinis, 
2009, p. 1/16).  CMS demonstrated inclusivity by convening an expert panel in the 
creation of these performance measures and by soliciting public comment (CMS). 
 
5.2 Conclusions  
 
The results of this study support prior research showing that care coordination 
efforts can improve patients’ health.  Care coordination interventions seem to be more 
effective on increasing the likelihood of meeting process measures compared to outcome 
measures where patient adherence is required to realize change in outcomes.  Having 
nationally established standards of care quality will allow for ready comparison across 
care settings, but the existence of such standards incentivizes treating to the test.   As 
such, the performance measures used to judge quality of care by accountable care 
organizations need to be continually updated to reflect medical advances and current 
best practices as these measures are likely to be a focus of care.  The National Quality 
Forum is the basis for nearly all performance measures; their purpose is to improve 
population health.  These same measures are doubling as performance targets through 
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organizational incentives offered by payers for increased quality of care and cost 
neutrality, conflicting with established performance management guidelines. 
 
5.3 Future Research 
 
In order to best realize improvements in population health, future research should test 
the strength of interventions implemented by ACOs to learn what changes to work 
processes have shown to be effective in helping patients meet defined performance 
measures.  Also paramount is a better understanding of costs associated with 
interventions targeted at improving population health in ACOs.  Continuing to validate 
and improve upon defined performance measures is also necessary to maintain the most 
appropriate care focus.  Research efforts should also consider health care providers 
perceptions of the quality performance measures to understand potential implications 
that may result on levels of job satisfaction, burnout, and perceived fairness.  Studies of 
performance management and their association to procedural and distributive justice 
seem appropriate at a time when pay for performance is increasing.  Care provided to 
patients is becoming increasingly collaborative through models of care that encourage 
collaboration between the care team (e.g., patient centered medical homes and ACOs).  
The changing nature of the delivery of health care services calls for research on how best 
to assess individual level performance in team settings.   
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APPENDIX A 
 
 
 
Table 15. Patient Characteristics Qualifying for Performance Measure 14 
 
  Total 
Treatment 
Group 
Control 
Group 
N 494 240 254 
Male (%) 34% 38% 31% 
Age 75 plus (%) 38% 34% 41% 
Age Mean 74 73 74 
White (%) 74% 76% 72% 
Black (%) 8% 6% 10% 
Other Race (%) 5% 3% 6% 
Hispanic (%) 42% 41% 43% 
Non-Hispanic (%) 38% 34% 41% 
Married (%) 39% 42% 37% 
Single (%) 50% 47% 52% 
Diabetic (%) 42% 41% 43% 
Hypertensive (%) 84% 81% 87% 
IVD (%) 20% 21% 19% 
Heart Failure (%) 6% 5% 7% 
CAD (%) 17% 18% 15% 
 
 
 
 
Table 16. Difference in Differences for Performance Measure 14 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 14 0.449 0.404 -0.045 0.358 0.458 0.100 0.145 
Std. Error  0.031 0.032 0.044 0.031 0.032 0.044 0.063 
t                     14.530 12.720 -1.010 11.600 14.420 2.260 2.310 
P>t 0.000 0.000 0.314 0.000 0.000 0.024 0.021 
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Table 17. Patient Characteristics Qualifying for Performance Measure 15 
 
  Total 
Treatment 
Group 
Control 
Group 
N 716 274 442 
Male (%) 34% 39% 31% 
Age 75 plus (%) 41% 35% 45% 
Age Mean 74 73 74 
White (%) 73% 75% 71% 
Black (%) 8% 6% 10% 
Other Race (%) 5% 4% 5% 
Hispanic (%) 38% 41% 37% 
Non-Hispanic (%) 41% 33% 46% 
Married (%) 36% 39% 33% 
Single (%) 49% 49% 49% 
Diabetic (%) 39% 40% 38% 
Hypertensive (%) 82% 80% 83% 
IVD (%) 20% 19% 21% 
Heart Failure (%) 7% 7% 7% 
CAD (%) 17% 17% 17% 
 
 
 
 
Table 18. Difference in Differences for Performance Measure 15 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 15 0.507 0.697 0.190 0.572 0.675 0.103 -0.088 
Std. Error  0.023 0.029 0.037 0.023 0.029 0.037 0.053 
t                     21.950 23.770 5.100 24.790 23.020 2.750 -1.660 
P>t 0.000 0.000 0.000 0.000 0.000 0.006 0.098 
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Table 19. Patient Characteristics Qualifying for Performance Measure 16 
 
  Total 
Treatment 
Group 
Control 
Group 
N 714 272 442 
Male (%) 34% 39% 31% 
Age 75 plus (%) 41% 35% 45% 
Age Mean 74 73 74 
White (%) 73% 75% 71% 
Black (%) 8% 6% 10% 
Other Race (%) 5% 4% 5% 
Hispanic (%) 39% 42% 37% 
Non-Hispanic (%) 41% 33% 46% 
Married (%) 36% 39% 33% 
Single (%) 49% 49% 49% 
Diabetic (%) 39% 40% 38% 
Hypertensive (%) 82% 80% 83% 
IVD (%) 20% 19% 21% 
Heart Failure (%) 7% 7% 7% 
CAD (%) 17% 17% 17% 
 
 
 
 
Table 20. Difference in Differences for Performance Measure 16 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 16 0.629 0.622 -0.007 0.597 0.943 0.345 0.352 
Std. Error  0.021 0.028 0.035 0.021 0.028 0.035 0.050 
t                     29.340 22.340 -0.190 27.860 33.860 9.830 7.090 
P>t 0.000 0.000 0.846 0.000 0.000 0.000 0.000 
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Table 21. Patient Characteristics Qualifying for Performance Measure 17 
 
  Total 
Treatment 
Group 
Control 
Group 
N 718 276 442 
Male (%) 34% 39% 31% 
Age 75 plus (%) 41% 35% 45% 
Age Mean 74 73 74 
White (%) 73% 75% 71% 
Black (%) 8% 6% 10% 
Other Race (%) 5% 4% 5% 
Hispanic (%) 38% 41% 37% 
Non-Hispanic (%) 41% 33% 46% 
Married (%) 36% 40% 33% 
Single (%) 49% 49% 49% 
Diabetic (%) 39% 40% 38% 
Hypertensive (%) 82% 80% 83% 
IVD (%) 20% 19% 21% 
Heart Failure (%) 7% 7% 7% 
CAD (%) 17% 17% 17% 
 
 
 
 
Table 22. Difference in Differences for Performance Measure 17 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 17 0.971 0.000 -0.971 0.998 1.000 0.002 0.973 
Std. Error  0.005 0.006 0.007 0.005 0.006 0.007 0.011 
t                     209.27 0.000 -129.750 215.12 170.38 0.300 91.960 
P>t 0.000 1.000 0.000 0.000 0.000 0.762 0.000 
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Table 23. Patient Characteristics Qualifying for Performance Measure 18 
 
  Total 
Treatment 
Group 
Control 
Group 
N 714 272 442 
Male (%) 34% 39% 31% 
Age 75 plus (%) 41% 35% 45% 
Age Mean 74 73 74 
White (%) 73% 75% 71% 
Black (%) 8% 6% 10% 
Other Race (%) 5% 4% 5% 
Hispanic (%) 39% 42% 37% 
Non-Hispanic (%) 41% 33% 46% 
Married (%) 36% 39% 33% 
Single (%) 49% 49% 49% 
Diabetic (%) 39% 40% 38% 
Hypertensive (%) 82% 80% 83% 
IVD (%) 20% 19% 21% 
Heart Failure (%) 7% 7% 7% 
CAD (%) 17% 17% 17% 
 
 
 
 
Table 24. Difference in Differences for Performance Measure 18 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 18 0.145 0.070 -0.075 0.118 0.779 0.662 0.737 
Std. Error  0.016 0.021 0.026 0.016 0.021 0.026 0.037 
t                     8.940 3.380 -2.860 7.270 37.760 25.220 19.860 
P>t 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
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Table 25. Patient Characteristics Qualifying for Performance Measure 19 
 
  Total 
Treatment 
Group 
Control 
Group 
N 497 203 294 
Male (%) 33% 36% 31% 
Age 75 plus (%) 14% 11% 17% 
Age Mean 71 71 71 
White (%) 71% 75% 69% 
Black (%) 9% 6% 11% 
Other Race (%) 5% 4% 5% 
Hispanic (%) 40% 44% 37% 
Non-Hispanic (%) 40% 32% 46% 
Married (%) 39% 43% 36% 
Single (%) 46% 45% 48% 
Diabetic (%) 40% 40% 39% 
Hypertensive (%) 82% 80% 84% 
IVD (%) 19% 19% 18% 
Heart Failure (%) 4% 4% 4% 
CAD (%) 15% 16% 14% 
 
 
 
 
Table 26. Difference in Differences for Performance Measure 19 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 19 0.248 0.296 0.047 0.262 0.217 -0.045 -0.092 
Std. Error  0.025 0.031 0.040 0.025 0.031 0.040 0.056 
t                     9.760 9.650 1.190 10.290 7.080 -1.130 -1.640 
P>t 0.000 0.000 0.235 0.000 0.000 0.257 0.101 
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Table 27. Patient Characteristics Qualifying for Performance Measure 20 
 
  Total 
Treatment 
Group 
Control 
Group 
N 174 70 104 
Male (%) 0% 0% 0% 
Age 75 plus (%) 0% 0% 0% 
Age Mean 68 68 68 
White (%) 74% 81% 68% 
Black (%) 9% 7% 11% 
Other Race (%) 5% 1% 8% 
Hispanic (%) 41% 46% 38% 
Non-Hispanic (%) 39% 29% 46% 
Married (%) 29% 31% 27% 
Single (%) 61% 60% 62% 
Diabetic (%) 39% 44% 36% 
Hypertensive (%) 83% 81% 84% 
IVD (%) 14% 17% 12% 
Heart Failure (%) 5% 3% 6% 
CAD (%) 10% 11% 10% 
 
 
 
 
Table 28. Difference in Differences for Performance Measure 20 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 20 0.375 0.471 0.096 0.327 0.243 -0.084 -0.180 
Std. Error  0.047 0.057 0.073 0.047 0.057 0.073 0.104 
t                     8.050 8.310 1.310 7.020 4.280 -1.150 -1.740 
P>t 0.000 0.000 0.190 0.000 0.000 0.253 0.083 
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Table 29. Patient Characteristics Qualifying for Performance Measure 21 
 
  Total 
Treatment 
Group 
Control 
Group 
N 153 58 95 
Male (%) 44% 50% 40% 
Age 75 plus (%) 42% 33% 47% 
Age Mean 74 73 75 
White (%) 76% 72% 79% 
Black (%) 5% 3% 5% 
Other Race (%) 6% 5% 6% 
Hispanic (%) 27% 33% 24% 
Non-Hispanic (%) 56% 45% 63% 
Married (%) 43% 45% 42% 
Single (%) 42% 41% 42% 
Diabetic (%) 20% 26% 17% 
Hypertensive (%) 22% 17% 24% 
IVD (%) 14% 14% 15% 
Heart Failure (%) 5% 3% 5% 
CAD (%) 12% 10% 14% 
 
 
 
 
Table 30. Difference in Differences for Performance Measure 21 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 21 0.284 0.414 0.130 0.253 0.810 0.558 0.428 
Std. Error  0.046 0.059 0.074 0.046 0.059 0.074 0.105 
t                     6.200 7.060 1.740 5.510 13.820 7.490 4.070 
P>t 0.000 0.000 0.083 0.000 0.000 0.000 0.000 
 
 
 83 
 
Table 31. Patient Characteristics Qualifying for Diabetes Performances Measures  
    (22, 23, 24, 25, and 27) 
 
  Total 
Treatment 
Group 
Control 
Group 
N 196 83 113 
Male (%) 35% 40% 31% 
Age 75 plus (%) 14% 11% 16% 
Age Mean 71 70 71 
White (%) 69% 81% 60% 
Black (%) 9% 5% 12% 
Other Race (%) 4% 1% 5% 
Hispanic (%) 57% 58% 57% 
Non-Hispanic (%) 29% 28% 30% 
Married (%) 41% 46% 38% 
Single (%) 45% 46% 45% 
Diabetic (%) 96% 96% 96% 
Hypertensive (%) 93% 89% 96% 
IVD (%) 25% 28% 23% 
Heart Failure (%) 7% 7% 6% 
CAD (%) 19% 24% 15% 
 
 
 
 
Table 32. Difference in Differences for Performance Measure 22 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 22 0.655 0.747 0.092 0.602 0.771 0.169 0.077 
Std. Error  0.043 0.051 0.067 0.043 0.051 0.067 0.095 
t                     15.060 14.720 1.380 13.830 15.190 2.530 0.820 
P>t 0.000 0.000 0.169 0.000 0.000 0.012 0.415 
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Table 33. Difference in Differences for Performance Measure 23 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 23 0.478 0.518 0.040 0.460 0.675 0.215 0.174 
Std. Error  0.047 0.054 0.072 0.047 0.054 0.072 0.101 
t                     10.260 9.530 0.560 9.880 12.410 3.000 1.720 
P>t 0.000 0.000 0.575 0.000 0.000 0.003 0.086 
 
 
 
 
Table 34. Difference in Differences for Performance Measure 24 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 24 0.628 0.651 0.022 0.531 0.807 0.276 0.254 
Std. Error  0.044 0.052 0.068 0.044 0.052 0.068 0.096 
t                     14.160 12.570 0.330 11.970 15.590 4.050 2.630 
P>t 0.000 0.000 0.744 0.000 0.000 0.000 0.009 
 
 
 
 
Table 35. Difference in Differences for Performance Measure 25 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 25 0.903 0.928 0.025 0.779 0.831 0.053 0.028 
Std. Error  0.033 0.038 0.050 0.033 0.038 0.050 0.071 
t                     27.690 24.390 0.500 23.890 21.850 1.050 0.390 
P>t 0.000 0.000 0.617 0.000 0.000 0.295 0.698 
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Table 36. Difference in Differences for Performance Measure 27 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 27 0.779 0.831 0.053 0.69 0.807 0.117 0.064 
Std. Error  0.039 0.046 0.061 0.039 0.046 0.061 0.086 
t                     19.75 18.07 0.87 17.5 17.54 1.93 0.75 
P>t 0 0 0.386 0 0 0.054 0.453 
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Table 37. Patient Characteristics Qualifying for Performance Measure 26 
 
  Total 
Treatment 
Group 
Control 
Group 
N 20 9 11 
Male (%) 40% 33% 45% 
Age 75 plus (%) 25% 22% 27% 
Age Mean 71 71 71 
White (%) 60% 67% 55% 
Black (%) 15% 0% 27% 
Other Race (%) 5% 0% 9% 
Hispanic (%) 60% 67% 55% 
Non-Hispanic (%) 20% 11% 27% 
Married (%) 40% 33% 45% 
Single (%) 45% 56% 36% 
Diabetic (%) 0% 0% 0% 
Hypertensive (%) 95% 89% 100% 
IVD (%) 100% 100% 100% 
Heart Failure (%) 10% 11% 9% 
CAD (%) 50% 56% 45% 
 
 
 
Table 38. Difference in Differences for Performance Measure 26 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 26 0.909 0.889 -0.020 0.818 0.778 -0.040 -0.020 
Std. Error  0.112 0.124 0.167 0.112 0.124 0.167 0.237 
t                     8.100 7.160 -0.120 7.290 6.270 -0.240 -0.090 
P>t 0.000 0.000 0.905 0.000 0.000 0.811 0.932 
 
 
 87 
 
Table 39. Patient Characteristics Qualifying for Performance Measure 28 
 
  Total 
Treatment 
Group 
Control 
Group 
N 531 200 331 
Male (%) 32% 36% 29% 
Age 75 plus (%) 38% 33% 41% 
Age Mean 73 73 74 
White (%) 72% 78% 69% 
Black (%) 9% 6% 11% 
Other Race (%) 4% 3% 5% 
Hispanic (%) 43% 45% 41% 
Non-Hispanic (%) 36% 29% 41% 
Married (%) 35% 40% 32% 
Single (%) 50% 50% 50% 
Diabetic (%) 45% 46% 45% 
Hypertensive (%) 100% 100% 100% 
IVD (%) 21% 20% 21% 
Heart Failure (%) 7% 7% 7% 
CAD (%) 18% 18% 18% 
 
 
 
Table 40. Difference in Differences for Performance Measure 28 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 28 0.598 0.570 -0.028 0.580 0.905 0.325 0.353 
Std. Error  0.025 0.033 0.041 0.025 0.033 0.041 0.059 
t                     23.530 17.430 -0.680 22.810 27.670 7.840 6.030 
P>t 0.000 0.000 0.496 0.000 0.000 0.000 0.000 
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Table 41. Patient Characteristics Qualifying for Performance Measure 29 
 
  Total 
Treatment 
Group 
Control 
Group 
N 128 49 79 
Male (%) 50% 59% 44% 
Age 75 plus (%) 48% 37% 56% 
Age Mean 75 73 76 
White (%) 77% 88% 70% 
Black (%) 9% 4% 11% 
Other Race (%) 3% 0% 5% 
Hispanic (%) 34% 33% 34% 
Non-Hispanic (%) 47% 41% 51% 
Married (%) 34% 47% 27% 
Single (%) 52% 39% 59% 
Diabetic (%) 50% 53% 48% 
Hypertensive (%) 86% 84% 87% 
IVD (%) 99% 98% 100% 
Heart Failure (%) 19% 16% 20% 
CAD (%) 80% 80% 81% 
 
 
 
Table 42. Difference in Differences for Performance Measure 29 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 29 0.443 0.531 0.088 0.557 0.694 0.137 0.049 
Std. Error  0.056 0.071 0.090 0.056 0.071 0.090 0.127 
t                     7.960 7.510 0.970 10.010 9.820 1.520 0.390 
P>t 0.000 0.000 0.331 0.000 0.000 0.129 0.698 
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Table 43. Patient Characteristics Qualifying for Performance Measure 30 
 
  Total 
Treatment 
Group 
Control 
Group 
N 128 49 79 
Male (%) 50% 59% 44% 
Age 75 plus (%) 49% 39% 56% 
Age Mean 75 74 76 
White (%) 77% 88% 70% 
Black (%) 9% 4% 11% 
Other Race (%) 3% 0% 5% 
Hispanic (%) 34% 33% 34% 
Non-Hispanic (%) 46% 39% 51% 
Married (%) 34% 47% 27% 
Single (%) 52% 39% 59% 
Diabetic (%) 50% 53% 48% 
Hypertensive (%) 86% 84% 87% 
IVD (%) 99% 98% 100% 
Heart Failure (%) 19% 16% 20% 
CAD (%) 80% 80% 81% 
 
 
 
 
Table 44. Difference in Differences for Performance Measure 30 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 30 0.848 0.878 0.029 0.886 0.898 0.012 -0.018 
Std. Error  0.037 0.048 0.061 0.037 0.048 0.061 0.086 
t                     22.650 18.460 0.490 23.670 18.890 0.200 -0.210 
P>t 0.000 0.000 0.627 0.000 0.000 0.844 0.838 
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Table 45. Patient Characteristics Qualifying for Performance Measure 31 
 
  Total 
Treatment 
Group 
Control 
Group 
N 42 17 25 
Male (%) 29% 35% 24% 
Age 75 plus (%) 57% 53% 60% 
Age Mean 77 76 77 
White (%) 76% 71% 80% 
Black (%) 12% 12% 12% 
Other Race (%) 5% 0% 8% 
Hispanic (%) 24% 29% 20% 
Non-Hispanic (%) 45% 29% 56% 
Married (%) 26% 24% 28% 
Single (%) 55% 53% 56% 
Diabetic (%) 48% 59% 40% 
Hypertensive (%) 90% 88% 92% 
IVD (%) 55% 53% 56% 
Heart Failure (%) 93% 88% 96% 
CAD (%) 48% 47% 48% 
 
 
 
Table 46. Difference in Differences for Performance Measure 31 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 31 0.760 0.706 -0.054 0.680 0.706 0.026 0.080 
Std. Error  0.092 0.112 0.145 0.092 0.112 0.145 0.205 
t                     8.230 6.300 -0.370 7.360 6.300 0.180 0.390 
P>t 0.000 0.000 0.710 0.000 0.000 0.859 0.698 
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Table 47. Patient Characteristics Qualifying for Performance Measure 32 
 
  Total 
Treatment 
Group 
Control 
Group 
N 112 46 66 
Male (%) 50% 61% 42% 
Age 75 plus (%) 49% 37% 58% 
Age Mean 75 74 76 
White (%) 76% 89% 67% 
Black (%) 8% 4% 11% 
Other Race (%) 4% 0% 6% 
Hispanic (%) 29% 26% 32% 
Non-Hispanic (%) 48% 48% 48% 
Married (%) 30% 46% 20% 
Single (%) 56% 39% 68% 
Diabetic (%) 46% 54% 39% 
Hypertensive (%) 84% 83% 85% 
IVD (%) 93% 89% 95% 
Heart Failure (%) 20% 22% 18% 
CAD (%) 97% 93% 100% 
 
 
 
 
Table 48. Difference in Differences for Performance Measure 32 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 32 0.697 0.674 -0.023 0.697 0.848 0.151 0.174 
Std. Error  0.055 0.066 0.086 0.055 0.066 0.086 0.121 
t                     12.670 10.230 -0.270 12.670 12.870 1.760 1.430 
P>t 0.000 0.000 0.788 0.000 0.000 0.080 0.153 
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Table 49. Patient Characteristics Qualifying for Performance Measure 33 
 
  Total 
Treatment 
Group 
Control 
Group 
N 60 28 32 
Male (%) 45% 50% 41% 
Age 75 plus (%) 42% 29% 53% 
Age Mean 74 73 75 
White (%) 73% 86% 63% 
Black (%) 12% 4% 19% 
Other Race (%) 5% 0% 9% 
Hispanic (%) 35% 39% 31% 
Non-Hispanic (%) 40% 32% 47% 
Married (%) 27% 39% 16% 
Single (%) 57% 43% 69% 
Diabetic (%) 82% 89% 75% 
Hypertensive (%) 87% 82% 91% 
IVD (%) 92% 86% 97% 
Heart Failure (%) 33% 32% 34% 
CAD (%) 95% 89% 100% 
 
 
 
 
Table 50. Difference in Differences for Performance Measure 33 
 
Outcome 
Variable     
Time 0 
Control  
Time 0 
Treated   
Baseline 
Difference 
 Time 1 
Control  
 Time 2 
Treated   
 Follow-up 
Difference 
Difference 
in 
Differences 
Performance  
Measure 33 0.750 0.821 0.071 0.781 0.786 0.004 -0.067 
Std. Error  0.074 0.079 0.108 0.074 0.079 0.108 0.153 
t                     10.140 10.390 0.660 10.570 9.940 0.040 -0.440 
P>t 0.000 0.000 0.511 0.000 0.000 0.967 0.663 
 
 
 
 
